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Abstract 
 
Currently, chronic diseases are one of the most common and expensive health conditions in the 
United States, with 133 million individuals suffering from at least one chronic disease. Tissue 
engineering, particularly mesenchymal stem or stromal cell (MSC) approaches, show great 
potential in meeting the need for treating chronic conditions. Current MSC therapies involve the 
use of microcarriers for the proliferation of cells. Microcarriers are difficult to accurately seed 
cells onto and keep cells in suspension without shearing off, but also difficult to fully harvest 
cells off of. Currently, there is a need for an improved scaffold to promote proliferation of 
adherent cells by maximizing surface area to volume ratio within bioreactors. This project aims 
to solve this gap in technology by constructing a 3-D scaffold of a novel material that would 
solve the issues in the production of MSC’s. A literature review was conducted to discover 
materials that were nontoxic, allowed cellular adhesion and could be formed into a 3-D scaffold 
for insertion into a bioreactor. Multiple experiments were performed to quantify cell seeding and 
proliferation on varying materials in order to select a material for final design. After four 
experiments a multilayer scaffold of stainless steel mesh was selected for final design. A proof of 
concept to compare overall efficiency to cell production gold standard could not be performed 
due to COVID-19 issues.  
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Chapter 1: Introduction 
 
Currently, chronic diseases are one of the most common and expensive health conditions 
in the United States, with 45% of the population or 133 million individuals suffering from at 
least one chronic disease [1]. Globally, the prevalence of chronic diseases is growing at an 
unprecedented rate with an expected increase of 57% by 2020. Other estimations suggest that by 
2020 chronic diseases will be responsible for approximately 75% of deaths world-wide [2]. 
Chronic diseases include such conditions as cancer, diabetes, hypertension, stroke, heart disease, 
respiratory diseases and arthritis [1]. Due to the rising levels of these diseases and the world’s 
population growing older and living long, with an estimate that by 2050, 17% of the world’s 
population will consist of individuals that are 65 years and older [3], there is also a growing 
clinical need to provide new and more effective treatments for these conditions.  
Tissue engineering, particularly mesenchymal stem or stromal cell (MSC) approaches, 
show great potential in meeting the need for treating the millions suffering from chronic 
conditions. Due to their superior clinical potential and properties, such as low immunogenicity, 
no teratoma risks, as well as immunomodulatory and migratory features, MSCs are already the 
leading cell type in clinical trials [4,5,6]. However, clinical trials are limited by the quantity and 
quality of MSC production. Cultivating MSC for clinical applications possess quite a challenge, 
because high-grade MSCs require suitable growth surfaces that cells can attach to and proliferate 
on, as well as exposure to an effective, ideally, chemically defined medium (CDM) for 
expansion [7]. Two-dimensional static culture systems that are commonly utilized for the 
expansion and cultivation of MSC possess important limitations, such as reduced cell numbers 
and compromise of cell functions [8].  
The overarching goal of this project is to develop a novel system or design to enable 
increased efficiency of large-scale growth of human mesenchymal stem cells (MSCs) by 
maximizing surface to volume ratio within a bioreactor. There is a growing need for the 
production of these cells and a market share estimated to reach 2,518.5 Million USD by 2026 
[9]. Need for effective MSC production processes is expanding each year. Processes for various 
clinical conditions such as treatment of severe graft-versus-host disease to cartilage repair are all 
assisted through the development of MSC production processes [10].  
The overall aims of this project include four major objectives. These objectives are:  
maximizing surface area to volume ratio of the system to allow for maximum cell adhesion and 
growth, increasing surface area utilization within the scaffold system, ease the harvesting process 
and increase harvesting efficiency, while creating a process that would be applicable to the 
industry. While keeping these objectives in mind, potential scaffold designs were explored and 
are outlined in the later chapters. These scaffold designs were tested to ensure that they meet at 
least one of the main four objectives and the corresponding results were quantified. These results 
provided an understanding of which scaffold designs possess the most industry potential. 
 
1.1 Project Scope          
The goal of this project is to step away from the current, yet very limited “gold standard” 
of both 2-dimensional MSC cultivation and cultivation of MSCs on spherical microcarriers by 
creating a new scaffold design to allow for cell adherence in media suspension within 
bioreactors.  
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Chapter 2: Literature Review 
 
2.1 Clinical Significance  
Currently, chronic diseases such as cardiovascular disease, cancer, chronic lung diseases 
and diabetes, account for 60% of the deaths globally [11]. Moreover, the prevalence of chronic 
diseases is growing at an unprecedented rate with an expected increase of 57% by 2020. Other 
estimations suggest that by 2020 chronic diseases will be responsible for approximately 75% of 
deaths world-wide [2]. Chronic diseases include such conditions as cancer, diabetes, 
hypertension, stroke, heart disease, respiratory diseases and arthritis [1]. Due to the rising levels 
of these diseases and the world’s population growing older and living longer, with an estimate 
that by 2050, 17% of the world’s population will consist of individuals that are 65 years and 
older [3], there is also a growing clinical need to provide new and more effective treatments for 
these conditions.  
Treatments for these chronic diseases, although various, are limited. Some of the 
treatments require less intervention, such as physical and psychological therapies, while others 
are more strenuous for the patient such as surgery and radiotherapy. Many of the chronic 
conditions are managed via medication, however such treatments have been shown to be very 
burdensome both for patients and the medical providers [12]. Chronic diseases are also widely 
accepted to not have a cure and cannot be prevented by vaccination, nor do they disappear [13]. 
For these reasons there is both a clinical need for novel treatments and demand for possible 
cures. 
Tissue engineering, particularly mesenchymal stem or stromal cell (MSC) approaches, 
show great potential in meeting this need for treating the millions suffering from chronic 
conditions. Due to their superior clinical potential and properties, such as low immunogenicity, 
no teratoma risks, as well as immunomodulatory and migratory features, MSCs are already the 
leading cell type in clinical trials [4,5,6]. However, clinical trials are limited by the quantity and 
quality of MSC production. Cultivating MSC for clinical applications possess quite a challenge, 
because high-grade MSCs require suitable growth surfaces that cells can attach to and proliferate 
on, as well as exposure to an effective, ideally, chemically defined medium (CDM) for 
expansion [7]. Two-dimensional static culture systems that are commonly utilized for the 
expansion and cultivation of MSC possess important limitations, such as reduced cell numbers 
and compromise cell functions [8].  
The growing global need for the production of human MSCs has been estimated and 
predicted to comprise a market share of $2,518.5 Million USD by 2026 [9].  
Currently, chronic diseases are one of the most common and expensive health conditions 
in the United States, with 45% of the population or 133 million American individuals suffering 
from at least one chronic disease [1]. According to a report by the National Health Council, the 
United States’ economic burden due to chronic disease is estimated to be $1.3 trillion annually 
[13].  
To quantify the need for MSC therapies present in the US, a special analysis was done on 
one of the most prevalent chronic conditions which is osteoarthritis. Osteoarthritis was selected 
for treatment quantification because therapies and treatments of this condition based on 
application of MSCs have been proven to be both safe and successful in phase I clinical trials [6].  
In one clinical trial it was found that the injection of MSCs with a count between 20 and 
24 million cells during one round of treatment produced positive results. Not only was the 
treatment able to reduce pain in the joints affected with osteoarthritis, but the effects of the 
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treatment lasted for up to 6 months. The treatment was also able to increase the thickness of 
cartilage at the affected sites, reversing some of the effects of osteoarthritis [6]. 
In another clinical trial it was shown that a single injection of 2 million MSCs derived 
from adult adipose, or fat, tissue was able to reduce pain significantly by clinical standards. 
Furthermore, the one injection of MSCs increased the overall function of the arthritic joints that 
were treated using the MSCs [14]. 
Using the data from the clinical studies mentioned above, in combination with estimates 
of 14 million people in the US suffering from osteoarthritis of the knee joint, we are able to 
calculate an estimation for the clinical demand of MSCs for patients with osteoarthritic knees 
[15]. By multiplying the number of cells used successfully per treatment by the number of 
patients that require this treatment we can calculate that the demand of MSCs for the treatment of 
this condition ranges between 28 and 308 million MSCs. 
Based on the particular analysis done above and the projected market growth described in 
the previous section, it is evident that there is a great need for the production of human MSCs in 
extremely high quantities annually. This need in turn creates demand in the biomedical industry 
for new designs and systems for MSC expansion that can make these production numbers 
possible.  
 
2.2 Mesenchymal Stem Cells  
Mesenchymal Stem Cells (MSCs) are a specialized class of cells of self-renewing cells 
that are able to differentiate into a multitude of other cell lineages [4]. Unlike embryonic stem 
cells, MSCs are adult stem cells and can be found in various areas of the body in adults. MSCs 
have the potential to differentiate into cells of the mesodermal lineage including osteocytes, 
adipocytes and chondrocytes. [16]. Beyond their ability for differentiation MSCs also possess the 
advantage of being immunomodulatory, or in other words they are able to produce and release 
such anti-inflammatory compounds as cytokines and immune-receptors. These 
immunomodulatory features have made MSCs a great potential means for treating chronic 
diseases. MSCs have also been shown to induce and assist in tissue regeneration, specifically 
they have been shown to be effective in regenerating bone and cartilage tissues [17]. MSCs are 
very resilient and can be easily harvested from the human body. Their culturing and expansion ex 
vivo is also a fairly straightforward process increasing the interest of the clinical community. 
MSCs are fairly abundant in the human body and they have been isolated and harvested from 
adipose tissue, bone marrow and dental tissues, as well as from new-born umbilical cord blood 
[18]. 
 MSCs are anchorage dependent stem cells, which means they cannot be cultured as single 
cell suspension in media but rather require a surface to attach and adhere to in order to proliferate 
[19].  
 
2.2.1 Current Clinical Trials  
 Several clinical trials have sought to better understand mesenchymal stems cells and their 
behavior in order to maximize their potential therapeutic opportunities. A 2016 study conducted 
by Salzig investigated human MSCs derived from both bone and adipose tissue sources in regard 
to their attachment, growth and spreading behavior on particular surfaces. The researchers 
investigated the effects of collagen type IV and fibronectin on the behavior of the stem cells, as 
well as different media compositions including serum-containing media and chemically defined 
media. The study demonstrated the success of fibronectin as a coating only for the growth of 
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MSCs derived from adipose tissue, while demonstrating the effectiveness of FGF-2 and collagen 
IV for the growth of bone derived MSCs. The study also showed preliminary results that the 
protein/peptide-free CDM was sufficiently successful in expanding different primary hMSCs 
supporting a theory that fewer supplements are necessary in the medium and that the cells can 
survive in basic medium [7]. 
 A 2016 study conducted by Tsai and colleagues sought to study hMSC expansion in a 
packed bed style bioreactor in contrast to the traditional microcarrier systems used to expand and 
grow mesenchymal stem cell populations while limiting cell differentiation. To do so, 
researchers seeded and grew cells in a bioreactor filled with Fibra-cel disks composed of 
polypropylene and non-woven polyester fibers. After nine days of culture, the cells had a 2.8 day 
population doubling time with homogeneous cell distribution in the fibrous bed. Notably as well, 
cells did not differentiate and maintained their properties as the packed bed system provided 
more ideal conditions than microcarriers. Cells experienced very low shear stress compared to 
microcarrier systems that have to continually be stirred to remain suspended and distribute 
oxygen and nutrients throughout the bioreactor system [20]. 
A 2018 exploratory study conducted by Athersys, Inc was done to understand the effects 
of their special and proprietary MultiStem treatment the goal of which was to treat individuals 
with acute onset of moderate to severe Acute Respiratory Distress Syndrome (ARDS). The 
study, conducted both in the United States of America and in the United Kingdom, included two 
parts. The first part was a small initial dose confirmation phase. The second part was a bigger 
double-blinded, placebo-controlled and randomized phase. Individuals began treatment within 
four days of their initial ARDS diagnosis although the average time between the diagnosis and 
the start of treatment was only two days. The study had a relatively small subject pool with only 
six subjects treated with MultiStem in the beginning stages and only 20 subjects were treated 
with an intravenous injection of 900 million MultiStem cells in the latter stages. The placebo 
group consisted of 10 subjects and also received an intravenous injection, however without any 
MultiStem cells. After their initial treatment, subjects were observed and monitored for a period 
of 28 days. Overall the results of the study showed that the individuals that received the 
MultiStem treatment had lower mortality (25%) in comparison to the mortality of the placebo 
group (40%). Patients treated with the MultiStem treatment also experienced fewer days on 
ventilators (40.2% lower) and in the intensive care unit (27.2% lower) [21].  
 
2.3 Bioreactors 
Bioreactors are an apparatus in which a biological reaction or process is carried out, 
especially on an industrial scale. Table 1 below lists several different types of bioreactors that are 
used for mass cell production as well as protein production. Each of the bioreactor type has 
advantages that make it useful for the production of specific cells and proteins. For example, 
there are bioreactors with minimal shear force in order not to stress the cells or induce 
differentiation. Also, some cell types need to adhere to a surface in order to proliferate. In order 
to better understand the different bioreactors that are currently on the market the table lists 
bioreactors types used, a brief description of how it works, the material that is used for the 
scaffold or walls, and finally the cell type that is typically used within that bioreactor.  
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Table 1: Current Bioreactors and Corresponding Material and Cell Type Supported 
Bioreactor Description Material Cell Type 
Micro-
carriers and 
scaffolds 
 
Porous micro- carriers were developed 
for mammalian cell recombinant protein 
production in stirred vessels 
Denatured type I 
collagen, negatively 
charged plastic particles, 
gellarin, cellulose, etc. 
Large variety, 
anchorage 
dependent 
Spinner flasks 
 
Spinner flasks are glass or plastic vessels 
with a central magnetic stirrer shaft and 
side arms for the addition and removal of 
cells and medium, and gassing with 
CO2- enriched air 
Variety of scaffolds 
MSCs with 
osteogenic 
differentiation 
Rotating- wall 
bioreactors 
 
A horizontally rotating cylinder which is 
completely filled with culture medium 
(no gas–liquid interface) rotates liquid 
inside at the same angular rate as the wall 
Biopolymers Osteogenic 
Wave 
bioreactors 
 
The wave bioreactor system provides a 
gentle wave motion for mixing, provides 
higher oxygen transfer than in spinner 
flasks, and has been shown to perform 
comparably with stirred- tank 
bioreactors for working volumes between 
1 and 100 L 
Polyethylene bags Large variety 
Column 
bioreactors 
 
Hydrodynamic principles that govern the 
flow pattern inside columns are applied 
to achieve uniform (plug) flow through 
the column 
Variety of scaffolds Cartilage 
Parallel plates 
 
The bioreactor consists of two primary 
compartments: a gas compartment that is 
separated from the bottom compartment 
by a gas- permeable, liquid-
impermeable membrane, and the liquid-
filled bottom compartment with a tissue 
culture plastic surface for support of 
anchorage- dependent cells 
Tissue culture plastic 
surface 
Osteogenic 
and 
anchorage-
dependent 
cells 
Hollow- fibre 
A hollow- fibre bioreactor is a two-
compartment system consisting of 
intracapillary and extracapillary spaces. 
Distribution of collagen, 
proteoglycan and 
glycosaminoglycan 
mammalian 
cells 
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bioreactor 
 
Intracapillary flow is distributed by 
headers to a hollow- fibre bundle that is 
potted in resin 
content 
Microfluidic 
bioreactors 
 
Microfluidic devices are fabricated using 
soft lithographic techniques originally 
developed by Whitesides and 
colleagues.122-125 
Poly(dimethylsiloxane) (PDMS), which 
is biocompatible,126 optically 
transparent, permeable to respiratory 
gases and elastomeric, is cast onto silicon 
wafers that have been patterned and 
profiled by photolithography 
Distribution of collagen, 
proteoglycan and 
glycosaminoglycan 
content silicon mold 
Large variety 
 
 
2.3.1 Current “Gold Standard” in MSC Expansion Systems  
The current “gold standard” in 2-dimensional MSC expansion is the Xpansion® 
Multiplate Bioreactor System that is offered by the Pall Corporation. This system utilizes a 
single-use 2D design with multiple plates stacked horizontally on top of each other that is used to 
allow for larger-scale production of adherent cells using traditional 2D cell culture techniques, 
with a maximum surface area of 122,400 cm2 [22]. The current solution to the limitations 
possessed by MSC expansion in 2-dimensional systems are microcarriers.  
 
2.3.2 Impeller Types and Flow 
For stirred tank reactors, the type of impeller used is directly related to the type of flow 
and shear stress the cell type can withstand for proper proliferation. Orientation of the impeller 
and agitation direction determines if the flow is either axial or radial. Axial flow is when the 
fluid is pushed up or down the shaft of the impeller while radial flow is when the fluid is pushed 
outwards from the shaft towards the bioreactor walls [23].   
 
Rushton  
The Rushton impeller is flat bladed with the blades vertical along the shaft. Position of 
the blades results in radial flow. The flat blades result in high shear forces on the cells and are 
best for non-shear sensitive cells such as yeast or bacteria [23].  
 
Pitched Blade 
A combination of radial and axial flow is achieved through the 45-degree angle of flat 
blades that are characteristic for pitched blade impellers. The blade angle allows for better 
mixing and higher oxygen mass transfer between the cells. The blades have lower shear force 
and are better for low shear cell lines or cells grown on microcarriers. The 45-degree angle and 
low shear force also makes viscous cultures achieve proper nutrient dispersion [23].  
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Gentle Marine Blade 
Similar to pitched blades, gentle marine blades also produce a combination of axial and 
radial flow. Gentle marine blades produce a much slower flow for lower shear cells and gently 
mix the medium [23]. 
 
Spin Filters 
Spin filters use marine blade impellers, but the impeller is enclosed in a screened cage. 
The cage design has small pores that prevent cells from entering the cage, keeping the cells 
closer to the bioreactor walls. A dip tube in the center of the reactor continuously withdraws 
media and recirculates it into the system. A media feed tube outside the reactor also provides a 
steady supply of fresh nutrients to the media as needed. While the mesh screen is a great way to 
keep cells separated from the media for media free harvest, the mesh can get clogged with cells 
and require replacement, making the system not ideal for repeated runs [23].  
 
2.3.3 Gold Standard Bioreactors  
There has been a growing interest in the use of disposable and single use technologies 
within the bioreactor systems. Studies utilized a single-use 3 L stirred tank bioreactor with 
collagen-coated microcarriers for expansion of MSC derived from bone marrow. The MSCs 
were left to propagate in the single-use 3 L bioreactor for 5 days. There was a 5.2 fold increase in 
total cell number from 30 to 150 million cells. Additionally, BM-MSC were propagated in a 
disposable stirred tank bioreactor achieving viable cell densities of 2.5-2.7x10^5 cells/mL during 
a 12 to14 day culture period [24]. 
Across the industry as a whole, there are several types of bioreactors that each serve their 
own specific need: rocking bed, stirred tank, rotating wall vessels, perfusion bioreactors, and 
insulation/expansion automated systems. Rocking bed bioreactors utilize single use bags that 
have limited scale up potential while some systems have a maximum volume of 500 L. Stirred 
tank bioreactors are the most versatile with a maximum volume of up to 1000 L, however the 
stirring systems are known to impact cell differentiation and viability. Rotating wall vessels, 
perfusion bioreactors, and insulation/expansion automated systems all fall into a class of ‘small 
scale’ bioreactors with volumes from 100 mL to as high as 10 L in the case of the rotating wall 
vessels. Rotating wall vessels and perfusion bioreactors each have low turbulence while 
perfusion bioreactors and insulation/expansion automated systems both utilize automation in 
their operation [25]. 
Current stir tank bioreactors are often single use due to the difficulty in reaching 
sterilization standards after a batch run. Common sellers of bioreactors have bioreactors with 
temperature control, robust industrial automation, scale-up ability and gas flow variability. Most 
bioreactors have the ability to have the control panel, gas flow, and pumps to be manipulated in 
order to adhere to a specific cell type's needs for growth. Bioreactors come in a range of sizes 
from benchtop bioreactors at 4.5L - 10L to scale- up bioreactors ranging from 50L - 2000L [26].  
 
2.4 Microcarriers  
Microcarriers most often come in the form of spheres or beads, manufactured from 
various materials including gelatin, cellulose, plastic and glass. They are most often ball-like 
scaffold structures that provide a necessary attachment surface for anchorage-dependent cells 
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suspended in culture, such as the culture used in bioreactors [27]. There are several types of 
microcarriers that have been developed over the past few years and although they are quite 
popular today and have been found to significantly increase the surface area available within a 
bioreactor they come with serious limitations and leave a lot of room for improvement.  
2.4.1 Solid Spherical Microcarriers 
One of the most popular microcarriers on the market is the Cytodex™ surface 
microcarriers. There are two types of Cytodex™ microcarriers, Cytodex™ 1 and Cytodex™ 3. 
Cytodex™ 1 microcarriers are made of a cross-linked dextran matrix combined with positively 
charged N, N-diethylaminoethyl groups. Cytodex™ 3 microcarriers are made of a matrix of 
cross-linked dextran and are covered in a thin layer of denatured collagen which is susceptible to 
the effects of trypsin. Cytodex™ microcarriers are advertised to have optimal size and density 
for cell growth and “high yields” of cultured cells. Dextran microcarriers are also advertised to 
possess advantages such as being biologically inert, strong but not rigid and transparent making 
microscopic examinations simple. A study comparing cell expansion on Cytodex™ microcarriers 
found that significantly high recovery rates were only achieved for cells grown on the collagen 
coated microcarriers. Cytodex™ 1 prices range from $391 for 25 gr to $3291 for 500 gr of dry 
powder microcarriers. Prices for the collagen coated Cytodex™ 3 microcarriers are higher with 
500 gr of dry powder microcarriers costing $3554 [28]. 
Another type of microcarriers available on the market are Corning microcarriers. These 
microcarriers are made of Class VI polystyrene and are available with a wide variety of surface 
treatments. Advantages of using these polystyrene microcarriers include a shorter preparation 
process, without the need for swelling and washing [29]. A study using Corning’s Synthemax II 
microcarriers for the expansion of MSCs found that the cultured cells had a cell attachment rate 
of between 80% and 90%, after a period of 24 hours from the initial seeding and a cell expansion 
of between 5-and 7-fold [30]. The price for 500 g of Synthemax II microcarriers is $6704 [31].  
2.4.2 Porous Microcarriers 
Porous microcarriers are designed to allow adherent cells to adhere within the structures 
by entering the pores along the structure shown in figure 1. The advantages of porous 
microcarriers include their ability to provide additional surface-area for cells to adhere to, while 
also providing a certain degree of protection from the hydrodynamic shear stress often created in 
stirred bioreactors [32]. Limitations of porous microcarriers include difficulty in oxygen and 
nutrients distribution within the microcarrier, as well as damaging waste accumulation within the 
pores [33,34].  
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Figure 1: Porous Microcarrier 
 
2.4.3 3D-shaped Hydrogel Cell Microcarriers 
The advantages of this novel microcarrier design include localized cell culture, shear-
stress shelter, flow alignment and ease of fine resolution high-speed imaging. However, these 
microcarriers are not very common and have yet to find application in the field of cell production 
[35].  
 
2.4.4 Liquid Microcarriers 
The main advantage of liquid microcarriers is their ability to create a special interface for 
anchorage-dependent animal cells. To overcome the limitations involved in culturing such cells 
on solid surfaces and the following collection of the cells, the liquid microcarrier system 
emerged. The liquid microcarriers provide the anchorage-dependent animal cells with a surface 
at the interface between the culture medium and a hydrophobic liquid to which they can adhere 
and then spread and proliferate on. Liquid microcarriers such as these possess additional 
advantages such as their simplicity and complete flexibility, thus allowing for the application 
within vessels of various shapes [33].  
 
2.4.5 Common Microcarrier Materials 
The majority of microcarriers are manufactured using both natural and synthetic 
polymers. Synthetic polymers used in microcarrier production include materials, such as 
polyhydroxyethylmethacrylate, polystyrene, polyacrylamide, polyurethane foam, polyethylene, 
polycarbonate, Perspex™, PVC, Teflon™, cellophane, and cellulose acetate. Natural polymers 
used in microcarrier production include gelatin, collagen, cellulose, glucose, chitin and chitosan, 
alginic acid and ECM [33]. 
 
2.5 2-D Static Culture Systems 
The currently and commonly utilized 2-dimensional static culture systems used in labs 
across the United States come with important limitations, such as reduced cell numbers and 
compromised of cell functions. Specifically, the current scale of these 2-D systems in lab settings 
is limited with surface areas ranging from 12.5 cm2 to 225 cm2, and although they are simple to 
operate and cost effective, a very large number of these systems would be necessary to produce 
enough MSCs for clinical trials. The use of multiple systems would be more time consuming and 
require more labor, while working with a very low surface to volume ratio. The chances of 
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contamination would also be increased, resulting in higher risk of cell deformation and death [8]. 
Other more modern expansion systems, like microcarriers and the vertical wheel design, that will 
be described in more detail below also come with serious limitations and difficulties, that result 
in their inability to meet the demand currently present on the US biomedical market. 
 
2.5.1 Current Scaffolds 
The current “gold standard” in 2-dimensional MSC expansion is the Xpansion® 
Multiplate Bioreactor System that is offered by the Pall Corporation. This system utilizes a 
single-use 2D design with multiple hydrophilized polystyrene plates stacked vertically on top of 
each other that is used to allow for larger-scale production of adherent cells using traditional 2D 
cell culture techniques, with a maximum surface area of 122,400 cm2. The stacked plates are 
placed within a stirred tank bioreactor. The compact design of the plates allows for a unique gas 
exchange system. Tubing runs down the center column of the plates and gas is exchanged along 
the plate channels. Each plate has 16 radial channels grooved into each plate which allows for 
media exchange along each plate. The impeller in the stirred tank bioreactor pushed the media 
upwards in axial flow and the media runs along the channels in the plate radially. The media 
moves up and over each plate running along the radial channels. Figure 2 shows the media flow 
route across multiple plates and channels. The channel design allows for equivalent media, 
nutrient and gas dispersion across all the plates and all the cells resulting in a more optimal yield 
[22].
 
Figure 2: Pall Xpansion® Multiplate Bioreactor System 
2.5.2 Wheel Bioreactors 
The wheel bioreactor is a new form of technology created by PBS Biotech. The wheel 
bioreactor is a vertically-oriented wheel which differs from traditional horizontal impellers. It is 
enclosed inside of the bioreactor vessel and rotates around a stationary shaft. It has unique 
features that separate it from today’s standard bioreactor systems. These features include a long 
wheel radius, peripheral paddles, and the rounded vessel bottom which contributes to the gentle, 
tangential fluid flow (Figure 3). It is composed of oppositely oriented internal vanes. These 
vanes impact the “cutting and folding” axial fluid flow pattern throughout the center of the 
wheel. It is a quick and efficient form of mixing with uniform particle suspension and dispersion. 
It generates low shear stresses in 50 mL to 500 L volumes. Additionally, it is scalable, using the 
same mixing parameters in the 50 mL and being able to apply them to a 500 L volume to achieve 
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a similar micro-environment.  
 Their innovation Vertical-Wheel™ Technology is driven by two different forms of 
power, MagDrive Technology and AirDrive Technology. In MagDrive, the Vertical-Wheel™ 
motion is powered by coupling between magnets on the wheel and the housing unit. This system 
has a number of advantages including; eliminating the need for anti-foaming agents or shear 
protectants, allowing for lower working volumes for in situ harvesting, optional secondary 
heating system for static seeding without temperature drop, and it is optimal for culturing shear 
sensitive cell aggregates or anchorage dependent cells on microcarriers. 
  
 
Figure 3: Wheel Bioreactor 
 
AirDrive Technology operates a little differently. The Vertical-Wheel™ motion is 
propelled by the buoyant force of gas bubbles (Figure 4). These gas bubbles are introduced from 
the sparger at the bottom of the disposable bag and are captured in the air cups on the impeller 
wheel periphery. The advantages of this driven system include; independent control of pH, 
dissolved oxygen (DO), and agitation through main gas sparger. There is inclusion of a 
microsparger which has customizable pore sizes in order to achieve high mass transfer rates, 
development of efficient CO2 stripping, and optimal high cell density suspension culture 
processes [36].  
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Figure 4: Wheel Bioreactor Propelled by Gas Bubbles 
 
 
2.5.3 Packed Bed Bioreactor 
Another new and advancing form of bioreactors are packed bed bioreactors. These types 
of bioreactors are completely filled with a material, such as polystyrene pellets, and are pushed 
together so that media can still flow through the system delivering the needed nutrients to the 
cells, and are close enough that cells can proliferate and expand across pellets. They are 
expanding in the world of medicine as a promising tool for tissue engineering applications. Some 
of the advantages of packed bed bioreactor over different types of bioreactors is the reuse of 
enzymes, continuous mode of operations, low substrate and product inhibition, high yield of 
desired product. Another advantage of packed bed bioreactors is their capability to support 
various cell lines for long culture periods, all while keeping shear conditions to a minimum. Low 
shear conditions are present in these packed bed bioreactors due to the immobilization of cells 
within macroporous matrices [37]. 
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Figure 5: Packed Bed Bioreactor Schematic 
Fibra - Cel Disks  
A microcarrier-like structure used in packed bed bioreactors are Fibra-Cel® Disks. For 
anchorage dependent cells, these disk structures act as a structure for adherence as well as 
increase the surface area within the reactor. The disks are made of non-woven polyester fiber and 
polypropylene mesh shown in figure 6. The mesh is electrostatically pre-treated to improve cell 
adherence onto the material. The matrix pattern on each disk not only provides a structure for the 
cells to adhere too, but also protects cells from damaging shear forces from the impeller fluid 
flow or gas bubbles [38]. Fibra-Cel® disks have a higher transfer of nutrients and oxygen versus 
standard microcarriers due to the matrix [39].  
 
Figure 6: Fibra-Cel Texture 
 
Nutrient Distribution and Waste Product Removal 
The main difference between the nutrient distribution and waste removal of perfusion 
bioreactors and stirred bioreactors is that perfusion has cells inside the bioreactor and continually 
removes cell waste products and media depleted of nutrients by cell metabolism, and adds fresh 
media to the cells at the same rate as the spent media is removed. Through this method new fresh 
media is constantly being supplied so the cells do not get caught in dead spots ensuring they get 
the proper nutrients and the waste is removed. In a stirred bioreactor however, the nutrients in the 
system are being constantly stirred around to make sure the entire media does not have spots 
where there are higher concentrations of nutrients or waste. 
 
2.6 Limitations of Microcarriers 
While microcarriers help slow down the shear forces on the MSC’s during growth in a 
stirred tank bioreactor, microcarriers can also pose a danger to the cells. The microcarriers move 
freely in the media, improving nutrient dispersion and media flow, but the spheres will often 
collide with one another damaging the adhered cells. Further damage can come from the 
spherical beads colliding with the impeller, bioreactor wall, or impeller shaft as well shearing the 
cells off the bead or damaging them [19,40]. 
 
2.7 MSC Limitations  
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As multipotent stromal cells, Mesenchymal Stem Cells have the ability to differentiate 
into numerous different cell lines, such as osteoblasts (bone cells), chondrocytes (cartilage cells), 
myocytes (muscle cells) and adipocytes. For each cell line there are different conditions that can 
induce the differentiation. The induction of osteoblast can be done by using human fibronectin, 
20 µg/mL or a 0.1% gelatin and coating a tissue culture plate and seeding cells with normal MSC 
growth media. After an overnight incubation and replacing the culture media with OsteoMAX-
XF™ Differentiation Media the cells will differentiate after 14-21 days. Also, other external 
forces can induce differentiation such as turbulence and fluid flow. Within a bioreactor there 
must be enough fluid flow to allow for proper distribution of nutrients within the system, 
however, the shear forces of the fluid cannot exceed 9 mL/min or else the MSC will begin to 
differentiate or die [41].  
 
2.8 Harvesting Techniques   
 Several methods are currently available for harvesting cells from microcarriers, the 
current gold standard in MSC production. The most common method is the use of proteolytic 
enzymes, such as trypsin or collagenase. Before washing the microcarriers in either of these 
enzymes, rinsing with PBS greatly increases the efficiency of the harvest. Aside from these 
standard procedures, dextranase can also be used for Cytodex™ microcarriers. Dextranase is 
able to completely digest these microcarriers while leaving the MSCs unharmed. Other less 
popular methods of harvest include sonication, chelating agents, exposure to hypotonic or cold 
conditions, and alteration of the surface tension of the culture media [42]. A 2014 study looked 
to enhance the efficiency of the manufacturers' generally suggested protocols by using 
trypsinization alongside agitation by increasing the rate of the impeller of the bioreactor for a 
short period of time. This adjustment increased the harvesting efficiency from as low as 5% to 
95% in some tests. The increased agitation did not impact the viability or differentiation of the 
MSCs, a concern when exposing MSCs to increased shear stresses [43].  
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Chapter 3: Project Strategy 
 
3.1 Initial Client Statement  
The project statement for the project was to develop novel coatings or systems to enable 
adherent cell growth within a bioreactor on microcarriers. 
 
3.2 Objectives and Constraints  
 
3.2.1 Overall Project Objectives  
The overall goal of this novel system is to maximize cell growth within a bioreactor by 
utilizing an increase in surface area to volume ratio. The chosen cells to which we want to 
increase cell growth are mesenchymal stem cells (MSC) due to the increasing prevalence of 
chronic diseases and the demand for new and effective cell-based treatments and therapies. In 
order to meet this demand, there is a need for modern and advanced production techniques of the 
required cells with the greatest clinical potential, MSCs. By increasing the surface area to 
volume ratios within a bioreactor system, we can increase the overall production of MSCs for 
clinical trials and future applications. Along with maximizing the surface area to volume ratio, 
we want to allow for proper flow and mixing of the media within the bioreactor. However, the 
flow speeds must be low enough not to damage or initiate differentiation of the cells with shear 
stresses, but also high enough to allow for nutrient dispersion throughout the system. Nutrient 
dispersion within the media is a key aspect when it comes to increased cellular growth. 
Additionally, we will need to incorporate some means of regulations of the media and the 
bioreactor system as a whole. This will include regulation of temperature, oxygen, CO2, etc, 
levels and sensor systems to track the levels of cell growth and nutrients within the media and 
alert and monitoring systems to notify the users when it is the accurate time to harvest.  
 
3.2.2 Design Requirements 
In order to ensure compatibility and minimum performance of our design, standards must 
be put into place. These technical requirements can be seen listed in Tables 2 and 3 show the 
chosen material of our design and the architecture of our design. 
 
Table 2: Material Technical Design Requirements 
Material 
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Design Requirement Value or Attribute 
Withstand Temperature 37° Celsius 
Maintain pH 7.0 - 7.4 
Allow for Cellular 
Adherence Greater than 50% surface utilization 
Inert Surface Chemistry Non-toxic and non-corrosive surface 
Table 3: Architecture Technical Design Requirements 
Architecture 
Design Requirement Value or Attribute 
High Surface Area to 
Volume Ratio Greater than 13,200 cm
2 per liter 
Sufficient Nutrient 
Distribution Sufficient O2 distribution and fluid flow 
Effective Harvest Greater than 5% recovery efficiency 
Scalable Scalable to commercial application 
 
 
3.2.3 MSC Growth Requirements  
One of the main functions of this design includes all aspects that keep the MSC healthy 
and proliferating. This will be accomplished through various design requirements. In order to 
maintain proper regulations for the development of MSC, the temperature must be maintained at 
37° Celsius and 5% CO2 level. This will be done through a means of an incubator incorporated 
into our design. A pH must also be maintained at 7.0-7.4. This will be done through our chosen 
media suspension. Additionally, in order to sustain MSC growth, there must be sufficient 
nutrient distribution throughout the chosen system. This will be accomplished through rotating 
propellers at the bottom of the bioreactor and an architecture that will allow for proper fluid flow 
and nutrient dispersion throughout the system [44]. 
 
3.2.4 Mechanical Requirements 
 There are mechanical aspects within the design that must be accomplished through our 
requirements. This includes maximizing the surface area to volume ratio to allow for the most 
MSC adhesion within our system. This will be expressed through our chosen design. Maximum 
adherence will not only be accomplished through a high surface area to volume ratio, but also 
through the chosen type of material. This material must allow for cellular adhesion of MSCs. 
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Minimal turbulence and fluid flow rate are a very strict requirements that were put into place. 
There must be enough fluid flow to allow for proper distribution of nutrients within the system, 
however, the shear forces of the fluid can-not exceed 9 mL/min or else the MSC will begin to 
differentiate or die which is not wanted within this design system [41].  
 
3.2.5 Feasibility Requirements 
 There are requirements within our design that were met in order to ensure the feasibility 
of our design. There must be an effective harvesting technique performed within 2 hours to 
preserve cell viability and to avoid differentiation [45]. The design must be able to become 
scalable to a commercial application. 
 
 
3.2.6 Ethical Standards  
 The ethical concerns associated with this project are with the methods, materials, and 
process used to enhance cell attachment. Throughout the process there must be assurance that 
any operators must not be exposed to or potential risk of hazardous or hazardous substances. 
Residues used for enhanced coatings on a scaffold must also not leach into the cell product for 
example polystyrene is not toxic to MSCs however are toxic within mammals. There are also 
considerations to take into account with the future clinical application for our scaffold design for 
cultured stem cells. There are many ethical concerns in today's society when it comes to using 
stem cells. For this particular design, we will be focusing on providing the necessary surface area 
for the growth of adult mesenchymal stem cells. Therefore, the ethical considerations and 
concerns associated with embryonic stem cells are not relevant in this discussion. The main 
ethical concerns for the clinical application of adult MSCs include unwanted differentiation of 
the MSC and their possibility to suppress anti-tumor immune responses and create new blood 
vessels that may lead to tumor growth [46, 47]. While we are unable to address the concern of 
anti-tumor immune response suppression within our system, we are able to control the unwanted 
differentiation. As mentioned before, this will be regulated through our fluid flow systems. A 
shear stress of 5 dynes/cm2 will not be exceeded within our system, in order to enable MSC 
proliferation, without forcing differentiation [41].  
 
3.3 Revised Client Statement 
The revised client statement is to develop a novel design to enable adherent cell growth 
of mesenchymal stem cells by maximizing surface to volume ratio within bioreactors, 
considering proper nutrient dispersion and keeping the shear stress on the cells below the 
minimum stress for differentiation while creating a cost-effective system.  
 
3.4 Management Approach 
 
3.4.1 Major Milestones  
1. Defining the scope of the project (9/18/19)  
2. Completing Background Research (11/8/19) 
3. Draft 1 of Report (9/18/19) 
4. Draft 2 of Report (9/25/19) 
5. Draft 3 of Report (10/2/19) 
6. Interviewing Stakeholders (11/30/19) 
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7. Selecting feasible designs from original brainstorms (12/6/19) 
8. Prototyping selected designs (1/24/20) 
9. Testing mechanical stresses on designs (shear forces, elastic modulus etc) 
(2/14/20) 
10. Cell culturing on designs (3/20/20) 
11. Analysis of cell growth over time (4/2/20) 
12. Analysis of harvesting ease/time of MSC off of the design (4/2/20) 
13. Final Report (4/16/20) 
14. Final Presentation of findings (4/16/20) 
 
 
 
3.4.2 Gantt Chart  
Figure 7: Gantt Chart 
 
3.4.3 Financial Statement  
Throughout the duration of this project, funding will be based on $250 per person, and 
will, therefore, have a total of $1,250. This will be put towards the acquisition of MSC’s as well 
as different materials for testing and lab fees.  We would like to keep our initial testing at a small 
scale no larger than a 100 sq. cm range to keep within our financial budget. Overall, we would 
like to create a microcarrier system that is low cost, in order to maintain feasibility of possible 
commercial use in the future. Ideally, our system would be produced and sold at a lower cost 
than our competitors’ products. For example, General Electric’s Cytopore® Microcarriers Beads 
or Xpansion® Multiplate Bioreactor System that is offered by the Pall Corporation. 
 
Table 4: Financial Statement 
Item Cost 
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Lab Fees $250 
Steel Mesh $15.99 
Fiberglass $17.99 
Filter Paper 100 µm $15.99 
Filter Paper 75 µm $7.99 
Total $307.96 
 
Chapter 4: Design Process  
 
4.1 Needs Analysis 
 
4.1.1 Need for MSC 
As has been previously stated, the need that the scaffold design will address is the 
production of more MSCs per volume in a bioreactor through the increasing of the surface area 
to volume ratio within the bioreactor. While there are various specific diseases and conditions 
that require MSCs for treatment and therapies, it was decided to quantify the need for 
osteoarthritis treatments specifically.  
Osteoarthritis was selected for treatment quantification because therapies and treatments 
of this condition based on application of MSCs have been proven to be both safe and successful 
in phase I clinical trials [15].  
In one clinical trial it was found that the injection of MSCs with a count between 20 and 
24 million cells during one round of treatment produced positive results. Not only was the 
treatment able to reduce pain in the joints affected with osteoarthritis, but the effects of the 
treatment lasted for up to 6 months. The treatment was also able to increase the thickness of 
cartilage at the affected sites, reversing some of the effects of osteoarthritis [6]. 
In another clinical trial it was shown that a single injection of 2 million MSCs derived 
from adult adipose, or fat, tissue was able to reduce pain significantly by clinical standards. 
Furthermore, the one injection of MSCs increased the overall function of the arthritic joints that 
were treated using the MSCs [15]. 
Using the data from the clinical studies mentioned above in combination with estimates 
of 14 million people in the US suffering from osteoarthritis of the knee joint, an estimation for 
the clinical demand of MSCs for patients with osteoarthritic knees can be made [48]. By 
multiplying the number of cells used successfully per treatment by the number of patients that 
require this treatment, the calculated demand of MSCs for the treatment of this condition ranges 
between 28 and 308 million MSCs. 
 
4.1.2 Need for New Suspended Media Expansion System 
There is a great need in the biomedical industry for new designs and systems for MSC 
expansion in suspended media. The currently and commonly utilized 2-dimensional static culture 
systems come with important limitations, such as reduced cell numbers and comprised cell 
functions. Specifically, the current scale of these 2-D systems in lab settings is limited with 
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surface areas ranging from 12.5 cm2 to 225 cm2, and although they are simple to operate and cost 
effective, a very large number of these systems would be necessary to produce enough MSCs for 
clinical trials. The use of multiple systems would be more time consuming and require more 
labor, while working with a very low surface to volume ratio. The chances of contamination 
would also be increased, resulting in higher risk of cell deformation and death [8].  
Microcarriers, which are the current gold standard for MSC growth, have their own 
shortcomings and limitations. The seeding process onto the microcarriers is a major limitation as 
the process is both time-consuming as well as inefficient. In an attempt to seed all microcarriers 
with cells, the bioreactor must be stirred and seeded multiple times, but even then, there will be 
many numerous microcarriers with no cells attached. In general, around a 50% seeding 
efficiency can be obtained through this process without dedicating large amounts of time for the 
process. An important aspect of this microcarrier efficiency is that if a microcarrier only has one 
or two cells adhere to it, then the cells will not have enough cell to cell interactions to properly 
proliferate and will therefore have that microcarrier end up with no cells attached. After the 
seeding process is complete and the cells are being cultured in the bioreactor, it is common for 
only around 50% of the surface area to be utilized, as can be seen in Figure 8 below. Another 
problem microcarriers face is that while the bioreactor is being stirred, the microcarriers are 
constantly colliding with one another, making it possible for the cells to completely shear off, 
again leaving the microcarrier with no cells attached. The final limitation associated with 
microcarriers is the inefficient harvest process, which under standard microcarrier harvest 
procedures only harvesting around 5% of the cells [43].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Microcarriers post seeding with the green circle showing an efficiently seeded fully 
confluent microcarrier, the red circle showing a microcarrier with no cells, and the blue circle 
showing a microcarrier with very few cells that will most likely not have enough cell to cell 
interactions to become confluent 
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4.1.3 Need for Operational Ranges 
There are several “needs” that our design must fulfill to be able to accomplish the greater 
goal of our project. The first mandatory criteria that our design must fulfill is to be functional 
under the predetermined operational ranges. Since most expansion processes of human MSCs 
have taken place in fully controlled rocking and stirred tank bioreactors with volumes ranging 
from 250 mL to 5 L, those are the bioreactor sizes that our scaffold design must be scalable for. 
The design should be able to support starting densities of MSC of approximately 15,000 cells per 
mL, while also being able to support harvesting densities of approximately 200,000 MSCs per 
mL. It needs to be able to function under agitation rates of approximately 64 rpm [49].  
Our design also needs to be able to ensure the necessary oxygen concentrations in all 
locations of the scaffold as oxygen concentration is another factor contributing to human MSC 
differentiation. 20% oxygen levels have induced adipogenic differentiation of human MSCs, 
while 5% oxygen content has greatly influenced chondrogenic differentiation. It has also been 
recorded that even short-term lack of the appropriate oxygen levels, as little as 48 hours under 
1% oxygen, can lead to irreversible damage to the differentiation potential of human MSCs, 
specifically into bone [10]. However, this significant lack of oxygen, known as hypoxia when 
fallen below 2%, can induce the formation and expression of certain vasculogenic characteristics 
[50]. Our design needs to make sure there are no “dead spots” within the scaffold where cells 
will experience hypoxia. 
Another criterion that our design must fulfill is a cost or price of no more than the budget 
we have allocated for this project, which is $1,250.  
 
4.1.4 Prioritizing Tasks   
 In order to prioritize the tasks our system needs to perform, a pairwise comparison was 
done shown in Table 5. Seven main goals were identified in order to create a successful system 
to improve production of anchorage dependent cells: maximizing cell growth, maximizing 
surface area to volume ratio, maximizing seeding efficiency, maximizing cell to cell interaction, 
maximizing harvesting efficiency, maximizing ease of manufacture, and minimizing cost. 
 
Table 5: Pairwise Comparison 
Task  A B C D E F G Score 
Cell Growth A X 1 1 1 1 1 1 6 
Surface Area to Volume Ratio B 0 X 1 1 1 1 1 5 
Seeding Efficiency C 0 0 X 1 1 1 1 4 
Cell to Cell Interactions D 0 0 0 X 1 1 1 3 
Harvesting Efficiency E 0 0 0 0 X 1 1 2 
Ease of Manufacture F 0 0 0 0 0 X 1 1 
Cost G 0 0 0 0 0 0 X 0 
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4.2 Design Requirements: Industry Standards  
The system, its operation, and the process used to design it must be in accordance with 
applicable international standards established by the International Organization of 
Standardization. Standards identified to be applicable are ISO 11737-2:2009 (Sterilization of 
Medical Devices), ISO 13485:2016 (Quality Management of Medical Devices), and ISO 
13022:2012 (Medical products containing viable human cells). ISO 11737-2:2009 gives criteria 
for tests to be used to define, validate, and maintain a sterilization process. These criteria will be 
critical for the design as the system will need to be sterilized in order to be used many times 
over. ISO 13022:2012 is designed to reduce the risk of hazards when designing, manufacturing, 
and testing medical devices utilizing human material. Abiding by this standard will guide the 
design of the system and testing of the system. Tests used to evaluate and validate the design 
must closely follow this standard to ensure the safety of all team members. Beyond testing, 
appropriate considerations must be made to ensure that the system is user-friendly, safe for an 
operator, and consistent in producing a safe product. Accordance with ISO 13485:2016 is 
specifically intended to ensure the production of consistent and high-quality medical products 
developed with a customer-centered focus and an emphasis on continual improvement. The 
standard identifies criteria for a quality management that spans the lifecycle of the product and 
its development, from design and development to servicing and maintenance. Accordance with 
these standards is critical in ensuring the safety of all stakeholders. 
 Aside from the standards listed above, there are additional standards that are designed to 
mitigate and eliminate hazards for operators of a bioreactor. Firstly, special precautions must be 
taken in order to reduce the risk of fire when working with potentially flammable additives, such 
as isopropyl alcohol. To reduce this risk, flammable resources must be stored in accordance with 
the requirements of 29 CFR 1910.106 and all wiring and equipment must be in accordance with 
EM 385-1-1, Section 11.G and NFPA 70 which includes, but is not limited to ground-fault 
protection. Some chemical hazards are also present while operating a bioreactor, specifically, 
exposure to carbon dioxide as a by-product of the system and exposure to waste and highly 
concentrated additives. OSHA standard 29 CFR 1910.146 specifies testing for carbon dioxide in 
confined spaces. Exposure to other waste products and hazardous additives is reduced or 
eliminated with the proper use of approved personal protective equipment (PPE), for example, 
nitrile gloves, face shields, splash aprons, and HEPA respirator filters [51]. 
 
4.3 Concept Map 
The below concept map outlines the overall goal of this project and means of 
accomplishing that goal (Figure 9). There are four methods that may be used to carry out the 
overarching goal to increase efficiency of MSC production: increase surface area to volume 
ratio, increase surface area utilization, increase seeding efficiency, and improve harvesting 
efficiency. This work did not directly work to ease harvesting efficiency, and instead, will focus 
on the three other methods. In order to increase surface area to volume ratio, novel structures 
including wrapped cylinders, anemone-inspired structures, and fibrous brush structures were 
explored. Methods for easing the seeding process include utilizing a single, rigid body structure 
and/or using a novel material that is faster/more adherent for MSCs. Lastly, to increase surface 
area utilization, a bioreactor system that compresses microcarriers creating a packed bed styled 
system was tested.    
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Figure 9: Initial Concept Map of Project Goals 
 
4.4 Conceptual Designs  
 Specific materials were chosen and selected to be run in each of the studies for individual 
reasons pertaining to nontoxicity, malleability (shaping the material into a desired construct), 
compression capability, surface area to volume ratio cellular adhesion abilities and cost.  
 Polystyrene is commonly used for all cell culture plates and flasks. Although, for our 
particular studies it was initially considered because of its ability to be spin coated onto any 
desired surface as well as its capabilities to be manipulated in order to form and hold pores in its 
structure through the addition of zinc oxide. This creates a porous surface of the spin coated 
polystyrene and increased surface area and textured surface for cells to adhere to. Pore sizes of 
50 nm and 200 nm were created to test their ability in cell attachment and proliferation. Glass 
slides were prepared and cleaned thoroughly by sonication then washed in acetone, isopropyl 
alcohol and deionized water for 10 minutes, repeated 3 times each. The glass slides of 
approximately 6.45 cm2 in area were then coated with a ZnO seed layer by spin-coating 5 mm 
zinc acetate dihydrate in ethanol at 2000 rpm for 30s and annealed at 350°C for half an hour in 
air. The ZnO seed determined the pore size, which were 50 nm and 200 nm as mentioned 
previously. 
 Polyurethane foam was chosen as a tested material because it has proven to allow for cell 
growth in multiple studies. However, one of the main reasons this material was chosen is 
because of this capability to be compressed or compacted into a packed bed. Furthermore, the 
foam is also porous, allowing for a large surface area for the cells to sink into and attach to. 
Polyurethane foam is also inexpensive and can be purchased and produced in large quantities.  
 Another testing material that was chosen for the studies was 304 Stainless Steel Woven 
Wire 120 Mesh. Stainless steel is a common material used in medical devices, including 
bioreactors. Because of this, it proved to be a promising material when testing cellular adhesion 
and proliferation. The stainless steel mesh also held other reasons for being chosen such as its 
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malleable capabilities. It has a wire diameter of 0.09 mm and apertures of 0.13 mm. This 120 
mesh design allowed for fluid flow through the scaffold, however also it was able to be shaped 
into any scaffold design needed. The woven mesh design also provided an increased surface area 
to volume ratio when compared among other design materials due to its woven construction 
format. Stainless steel mesh is mass produced and can be purchased at a cost of $0.25 per 100 
cm2. 
 Lastly, fiberglass was chosen as a tested material because of the proven effectiveness of 
culturing cells on glass slides. It has been known that cells adhere and grow on certain types of 
glass. Fiberglass was chosen because of its cell growth capabilities and its ability to be packed 
together in shreds to allow for a greater surface area to volume ratio. Fiberglass is inexpensive 
and can be produced or purchased in large amounts.  
 
4.4.1 Material Cell Loading 
 Human fibroblast cells were obtained from Professor Page and were cultured to 
confluence in a T75 flask. 
The materials were seeded with 70 µL of cell suspension. The seeded materials were then 
incubated for 15 minutes, removed from the incubator and additional media was added to 
prevent drying out. After 3 repetitions the materials were viewed under the microscope to verify 
that cells were attached and then the wells were filled, and cells were incubated for a time period 
between 4 and 7 days and medium was changed every other day. 
 
4.4.2 Harvesting and Cell Counting  
 A procedure designed to test overall seeding potential, proliferation, and effective 
harvesting of cells on potential materials was utilized. These new materials identified through 
research, as well as control substrates already used by the industry, were seeded with the same 
quantity of MSCs from the same cell line and given 15 minutes to attach to the new substrate. 
After given time to double several times, approximately 7 full days the cells on all samples were 
trypsinized, harvested, and counted using a hemocytometer. The protocol is found in Appendix 
D. 
 
4.4.3 BrdU Assay  
 A BrdU assay is used to test and verify proliferation of cells on novel materials that may 
pose challenges while harvesting. BrdU, or Bromodeoxyuridine, is an analog of the nucleoside 
thymidine that is incorporated into the cells’ DNA during the DNA synthesis phase of the cell 
cycle. BrdU is detected by first incubating methanol fixed cells with a mouse anti-BrdU antibody 
followed by incubation with an Alexafluor-488 conjugated anti-mouse IgG1 antibody. Lastly, 
Hoechst 33342, a fluorescent-blue nucleoside stain, is incorporated and binds to the DNA of 
each cell in the culture (shown in Figure 10). Therefore, under fluorescent light, green 
fluorescence will show each cell that had undergone DNA synthesis during the BrdU incubation 
period while blue fluorescence shows all cells in that culture (shown in Figure 11). From this, 
proliferation of cells on materials can be verified based on the proportion of newly divided cells 
in a culture and the total number of cells. The protocol is found in Appendix E. 
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Figure 10: Collagen Coated Mesh Fluorescent-Blue Stain of Fibroblast Cells 
 
 
Figure 11: Collagen Coated Mesh Fluorescent-Green Stain of New Fibroblast Cells 
 
 
Figure 12: Collagen Coated Mesh Image Overlay of Original Cells and Newly Proliferated 
Fibroblasts 
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4.4.4 Relevant Design Calculations For Experimental Parameters 
Relevant equations consist of those around the quantification of cells in order to prove 
that the material is beneficial. Some of these equations include cell recovery which will tell us 
what percentage of the cells are still alive at harvest as compared to those that were alive at 
seeding. Another equation is viability, which is the percent of live cells versus dead cells. 
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(      	  	     	     ) ×100 
Figure 13: Relevant Equations 
 
4.5 Preliminary Experiments  
 Our initial material testing involved seeding 20,000 umbilical cord hMSCS in a volume 
of 150 µl. This experiment was designed to give us initial insight on what materials were most 
promising for adherent growth and should be continued on further. Materials chosen for this 
experiment were polyurethane foam, polystyrene 50 nm pore size, polystyrene 200 nm pore size, 
polystyrene nonporous, collagen coated mesh, plain glass and collagen coated mesh. This 
selection of materials encompasses materials from our conceptual designs as well as using 
industry standard materials of collagen and glass to promote cell adhesion which we will use as a 
baseline to compare to our materials. Each sample of cells was dropped on a single piece of each 
material. The seeded materials were incubated for fifteen minutes to allow the cells to attach to 
the material substrate. Then the sample was removed from the incubator and 100 µl of complete 
media was added to the surface. The sample was then placed back in the incubator for another 15 
mins. This procedure was repeated 3 times. After 45 minutes, the well with the sample was filled 
with media and the seeded surface was submerged in media. 
There were 3 pieces of each in order to calculate the average growth rate and doubling 
time between samples of the material (Figure 14). After 4 full days for the cells to grow, the 
materials were removed from the media and placed in a fresh dish. The sample was then rinsed 
in DPBS (Ca2+/Mg2+-free) and the sample was submerged in 3ml of Trypsin and incubated for 10 
minutes. After adequate trypsinization, media was added, and the cells were counted using a 
hemocytometer. Cell yield, growth rate, and doubling time are presented below in Table 6.  
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Figure 14: Material Testing 1 Schematic  
 
Table 6: Material Results Test 1: 4 Days 
Material Cells Seeded Average Yield (After 4 Days) 
Growth Rate 
(% Daily) 
Doubling Time 
(Days) 
Collagen Coated 
Glass Slide 20,000 60,000 50 2.52 
Plain Glass Slide 20,000 40,000 25 4.000 
Polystyrene (50 nm) 20,000 34,375 17.97 5.119 
Polystyrene (200 nm) 20,000 28,125 10.16 8.132 
Collagen Coated 
Mesh 20,000 18,750 -1.56 -0.395 
Polyurethane 20,000 4,150 -19.81 -1.763 
Polystyrene 
(Nonporous) 20,000 - - - 
 
34 
 
Figure 15: Material Testing 1 Growth Rates Bar Chart 
 
A second experiment was performed to mimic and improve results of the first 
experiment. This experiment used human fibroblast cells. The schematic of the 6 well plates are 
shown below in Figure 16. Two samples of each material were used and seeded with 100,000 
fibroblast cells each. The materials selected for this experiment were collagen coated stainless 
steel mesh, 200 nm pore sized polystyrene, 50 nm sized pore polystyrene, glass, a control of the 
bottom of the well and polyurethane foam. These materials encompass promising materials from 
experiment 1 as well as incorporating collagen to improve stainless steel mesh results and a 
control result from the plain well plate. 15 minutes were given to allow cells to adhere 2 mL of 
media was placed in each well in order to fully submerge the sample in the media. The media 
was changed every other day and the cells were given 7 full days to grow. Each sample was 
removed from the media and placed in a fresh dish. The sample was then rinsed in DPBS 
(Ca2+/Mg2+-free) and the sample was submerged in 3 ml of Trypsin and incubated for 10 
minutes. After adequate trypsinization, media was added, and the cells were counted using a 
hemocytometer. Cell yield, growth rate, and doubling time are presented below in Table 7. 
 
 
Figure 16: Material Testing Culture Dish Schematic 
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Table 7: Material Testing 2: 7 Days 
Material Cells Seeded Sample 1 Sample 2 Average Growth Rate (% Daily) 
Doubling Time 
(Days) 
Cell Culture Dish 100,000 435,000.00  405,000.00  420,000.00  45.7 3.381 
Glass 100,000 262,500.00  502,500.00  382,500.00  40.36 3.617 
Porous Polystyrene 
(200 nm) 100,000 480,000.00  247,500.00  363,750.00  37.68 3.757 
Porous Polystyrene 
(50 nm) 100,000   382,500.00  142,500.00  262,500.00  23.21 5.027 
Collagen Coated 
Mesh 100,000 7,500.00  60,000.00  33,750.00  -9.46 -4.467 
Polyurethane 100,000      -       -      -    - - 
 
 
Figure 17: Material Testing 2 Growth Rates Bar Chart 
 
After concluding the experiment and analyzing the results of the polyurethane foam it 
was decided the harvesting of this material was too difficult and impractical for industry use. 
Stainless steel mesh continued to be pursued as a viable option in further experiments because 
the flexibility of the structure and high surface to volume ratio would be beneficial for large scale 
manufacturing of MSCs.  
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A third experiment was performed in order to quantify newly proliferated cells on 3-
dimensional materials. 100,000 cells were seeded on the seven material samples and given 72 
hours to adjust to the new environment. Materials for experiment 3 were collagen coated mesh, 
polystyrene 50 nm pore size, polystyrene 200 nm pore size, mesh soaked in culture medium, 
plain mesh, and fiberglass. These materials encompass the new materials for a structure that we 
believe are most promising based on the previous 2 experiments as well as the addition of 
fiberglass as an alternative option for a structure design. Specifically, this experiment will be 
used to validate the 3 types of mesh since the cells falling through the pores will not be counted 
and the adhesion to the structure and proliferation on the structure is the focus of the experiment. 
The BrdU was then added to the samples 24 hours prior to imaging in order to stain the newly 
proliferated cells DNA for imaging. After images were collected showing the seeded cells, newly 
proliferated, and an overlay image of both stains ImageJ was used in order to count and quantify 
results. Table 8 shows the comparison between original and newly proliferated cells at the 
sample site on each sample. The results are present in Figure 18 for easier visualization. The 
control, collagen coated mesh, soaked mesh and plain mesh all had more newly proliferated cells 
on the material than original cells. This data is promising in pursuing mesh as a viable 
architecture as it is presenting to be a suitable environment for large amounts of cell growth.  
 
 
Table 8: BrdU Assay Results of Seeded Cells Versus Proliferated Cells 
 Control CCM Polystyrene 50 nm 
Polystyrene 
200 nm 
Soaked 
Mesh Plain Mesh Fiberglass 
Original 
Number of Cells 1037 350 239 614 370 177 337 
Newly 
Proliferated 
Number of Cells 
1539 353 103 546 567 197 n/a 
 
 
Figure 18: Results of BrdU Assay Bar Chart 
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 Soaking the mesh in cell medium (Appendix F) resulted in improvement between initial 
cell adhesion on the mesh during seeding as well as large improvement on the number of newly 
proliferated cells. The initial seeding on the soaked mesh was approximately double of the plain 
mesh and the newly proliferated cells on the soaked mesh was approximately triple that on the 
plain mesh. Improving proliferation on the mesh led to a further experiment that aimed to 
eliminate cells falling through the pores without limiting flow between pores.  
A fourth experiment was performed after analyzing the results of the previous study. It 
was decided to continue testing on mesh that was not coated in collagen as it appeared to clog 
pores and limit cell motility on the material. Alternatively, mesh was soaked in complete growth 
medium for 4 days prior to cell seeding. Plain non-soaked mesh was also seeded along with a 
new chosen material, fiberglass. The 5 layers of mesh were laid over one another in order to 
mitigate cells falling through the mesh holes. The fiberglass was also layered over one another in 
order to enhance cell seeding efficiency.  All material samples were seeded with 100,000 
fibroblast cells. The cells were allowed to grow for 6 days before being trypsinized and counted 
using a hemocytometer. Overall, soaked mesh showed the best results with the highest growth 
rate shown in Table 9. This matched the observed data seen in the BrdU study of mesh being a 
suitable environment for adherent cell growth.  
 
 
Table 9: Architecture Material Testing 3: 6 Days 
Material Cells Seeded Sample 1 Sample 2 Average Growth Rate (% Daily) 
Doubling Time 
(Days) 
Soaked Mesh 100,000  1,775,000    725,000    1,250,000  191.66 1.647 
Plain Mesh 100,000   1,575,000    900,000    1,237,500  189.58 1.653 
Fiberglass 100,000   435,000   405,000    420,000 53.33 2.898 
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Figure 19: Material Testing Growth Rates Bar Chart 
 
After performing architecture material testing, structural calculations and pressure drop 
experiments were performed in order to assess the viability of nutrient dispersion and surface 
area to volume ratios of each of the chosen materials. A miniature chamber was developed in 
order to recreate a bioreactor simulation. Each of our materials were packed within the tubing 
shown in Figures 21 and 22 and were tested or fluid flow rates and pressure drops. The results 
can be seen in Table 10. 
 
 
Figure 20: Pressure Drop and Fluid Flow Setup 
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Figure 21: Packed Bioreactor Setup 
 
Table 10: Flow Rate and Pressure Drop Results 
 Control 
Packed 
Mesh 
Disc 
Design 
Rolled 
Mesh 
Cylinder 
Design 
Packed 
Fiberglass 
Design 
Packed Foam 
Polyurethane  
Packed 
Microcarriers 
Flow Rate 
(mL/min) 
160  140   170  120  N/A N/A 
Pressure 
Drop (in) 
4.5 4.5  3.0 6.0 10 10 
 
Calculations were also performed in order to find the surface area to volume ratio of the 
fiberglass and stacked mesh disks. These surface areas were compared against the industry 
golden standard which is microcarriers. These results can be seen in the bar chart shown below 
(Figure 22).  
 
 
Figure 22: Surface Area Results 
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4.6 Final Design Selection 
 From preliminary material and architecture testing, three alternative designs have been 
identified: Stainless Steel Mesh Stacked Disks, Stainless Steel Mesh Cylindrical Roll, and 
Porous Polystyrene Packed Shards. This section will assess each design against key requirements 
and attributes and identify a final design. 
 The Stainless Steel Mesh Stacked Disks and Stainless Steel Mesh Cylindrical Roll were 
chosen because they offer the greatest improvement in surface area-to-volume ratio comparing to 
microcarriers, as they can provide 148,451 cm2/L while microcarriers can only provide 13,200 
cm2/L. These two designs were also selected because they allowed for sufficient fluid flow when 
packed together, indicating that they would not obstruct appropriate nutrient dispersion and 
waste elimination. The stainless steel mesh material used in these designs was chosen due to its 
ability to support cell adherence and proliferation, as well as non-toxic and non-corrosive nature. 
The other reasons stainless steel mesh was chosen as the base material for this design is because 
of its flexible and moldable nature, which allowed us to create the desired architectures. 
Although other materials such as plain glass and cell culture plastic have a definite advantage in 
supporting cell adhesion and proliferation, they are not viable options for a scaffold design 
within a bioreactor precisely because they lack the flexibility and compliance provided by 
stainless steel.  
 The Porous Polystyrene Packed Shard design was selected because throughout our tests 
the polystyrene coating with a pore size of 200 nm showed the highest cell attachment and 
proliferation. As this material was the most successful in our tests it was chosen as a coating for 
our scaffold design. There were several limitations due to the coating technology, so based on 
that we made a decision to stick with glass as the sub-substrate and use a packed glass shard 
design with polystyrene coating.  
 
4.6.1 Alternative Designs 
 The first of the alternative designs (Design #1) is the Stainless Steel Mesh Stacked Disks. 
This design consists of circular cut disks from the woven mesh. The circles can be cut to fit any 
desired size the bioreactor needs. The stainless steel wire is approximately 0.09 mm in diameter. 
The wires are separated with an aperture of 0.13 mm. The mesh is 304 stainless steel material 
which is non-corrosive, sturdy and durable. This design is representative of a packed bed 
chemical reactor design. The disks are stacked over each other in a fanned set-up in order to 
decrease the openings throughout the stacked bed. It is stacked for this reason in order to limit 
the number of cells falling through the packed bed when initial seeding takes place. These 
circular mesh cut-outs were to be soaked in culture medium for 24 hours prior to culturing within 
the bioreactor. From preliminary material testing, stainless steel mesh soaked in culture medium 
is shown to support adherent cell growth at a similar efficiency as collagen coated stainless steel 
mesh at a fraction of the cost. The packed system also allows for a high surface area to volume 
ratio with plenty of contact between neighboring disks, allowing for increased cell to cell 
communication and migration. The stainless steel mesh material also provides little resistance to 
media and nutrient flow, enabling sufficient nutrient and oxygen distribution throughout the 
packed bed. 
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Figure 23: Stainless Steel Mesh Disk 
 
 
Figure 24: Design #1: Stainless Steel Mesh Disks Stacked  
 
 The second of the alternative designs (Design #2) is the Stainless Steel Mesh Cylindrical 
Roll. This design consists of the same material as the woven mesh circular disks in Design #1, 
however the mesh is spun into a cylinder shape as shown above. The length of the cylindrical roll 
can be cut to fit any desired size the bioreactor needs. The stainless steel wire is approximately 
0.09 mm in diameter. The wires are separated with an aperture of 0.13 mm. The mesh is 304 
stainless steel material which is not easy to rust, sturdy and durable. Additionally, it is very 
bendable and can maintain the curved shapes as shown below. The stainless steel is rolled 
loosely to create space for media, oxygen, and nutrients to flow vertically through the system. 
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Therefore, there is a lack of contact between surfaces within the system, limiting cell to cell 
communication and migration to only a single plane of mesh. This stainless steel mesh is soaked 
in culture media prior to culture similar to Design #1. The architecture of this design provides 
less surface area to volume ratio compared to Design #1, but also offers ease of manufacture and 
a lesser cost of goods to produce. 
 
 
Figure 25: Design #2: Stainless Steel Mesh Cylindrical Rolls 
 
 The third of the alternative designs (Design #3) is the Porous Polystyrene Coated 
Fiberglass. This design, similar to Design #1, is representative of a packed bed design. However, 
in this design the packed material is made of glass shards coated with polystyrene with 200 nm 
pours. In preliminary material testing, porous polystyrene was able to support adherent cell 
growth with efficiency competitive with industry standard materials. The packed bed design 
offers similar cell to cell advantages as Design #1, however, the porous polystyrene coated glass 
offers less overall surface area compared to the stainless steel mesh material. Additionally, 
porous polystyrene coated glass has a more intensive and more expensive manufacturing process 
compared to the soaked mesh material in alternative Designs #1 and #2. 
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4.6.2 Final Design 
Based on the below pairwise analysis, Design #1 (Stainless Steel Mesh Stacked Disks) 
was selected as the final design. 
 
Table 11: Final Design Pairwise Analysis 
Attribute Weight Design #1 Design #2 Design #3 
Cell Growth 7 0 0 1 
Surface Area to Volume Ratio  6 1 0 -1 
Seeding Efficiency 5 0 1 1 
Cell to Cell Interactions 4 1 0 0 
Harvesting Efficiency 3 0 1 -1 
Ease of Manufacture 2 1 1 -1 
Cost 1 1 1 -1 
Total  13 11 0 
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Chapter 5: Design Verification 
 
5.1 Proof of Concept Methodology 
 To verify the final design, a small-scale bioreactor containing the final design: Stainless 
Steel Mesh Stacked Disks. This small-scale bioreactor will be attached to a continuous flow 
pump that will induce continuous flow and fresh media into the bioreactor, a separate 
oxygenation pump will provide constant oxygen input to the system. The stainless steel mesh 
disks will be cut to the same diameter as the bioreactor interior and soaked in media for at least 
24 hours prior to culturing. Disks will be stacked to half the height bioreactor. The system during 
the culturing process will be placed in an incubator maintaining 37℃ and 5% CO2.  
To start the culture, mesenchymal stem cells will be seeded to the top disk. The holes 
within the mesh would allow for cells to pass through to the lower disks and seed through the 
structure. The culture will last for 4 days, after which cells will be trypsinized, agitated, 
harvested, and counted. After the conclusion of this experiment, adjustments will be made to 
eliminate any shortcomings identified within the small-scale bioreactor, such as nutrient flow 
rate, seeding strategy. The same experiment will be repeated; however, it will have a duration of 
7 days. After the conclusion of the two experiments, results will be analyzed to determine the 
overall output of the system. This output will be compared to the output of a system with the 
same volume that utilized microcarriers. 
 
5.2 Anticipated Results  
 For the initial culture proof of concept testing that lasted for 4 days, results were 
anticipated to verify the viability of this design as a method for high mesenchymal stem cell 
production. Over the course of the 4 day culture, the cells, on average, would double every 30 
hours after an initial lag period for adjustment to the new surface as has been seen throughout the 
initial material proliferation testing. Over the course of the 7 day culture, the cells would have a 
lower doubling time of 24 hours as the lag period present has less of a statistical impact over the 
longer time frame. Inspection of the mesh disks after the harvesting process would reveal that 
some cells were not successfully trypsinized and harvested. After the harvesting process was 
repeated, it would show that about 20% of the total cells remained on the structure and an 80% 
harvesting efficiency. These anticipated results translate to overall efficiency and production 
output greater than the industry standard microcarriers. 
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Chapter 6: Final Design and Validation 
 
6.1 Economics  
Economically, the successful implementation of our project would positively 
impact the economy of everyday living by lowering the cost of drug treatments for 
patients with chronic illnesses. The average American with a lifelong chronic disease 
spends 5,300 USD per year on drugs, therapies, and hospital visits. This yearly cost can 
accumulate upwards of 150,000 USD for a patient living with a chronic disease for 30 or 
more years [52]. The ability to mass produce mesenchymal stem cells for patient specific 
therapies would alleviate the need for expensive drugs as well as possible elimination of 
the need for drugs for treatment. A MSC treatment for chronic disease would be roughly 
10,000 USD [53].  Initially, a patient specific therapy would be costly, but overtime the 
treatments will be less expensive and ultimately more cost effective as a treatment then 
years on other lifelong drug therapies.  
Overtime, as our product became more streamline in the pharmaceutical industry 
and more labs adopted our scaffold for large scale production of MSCs, total cost for 
treatment would also reduce. As larger batch runs yield large densities of cells, one single 
run could in theory treat multiple patients for the same chronic disease or smaller patient 
specific runs could be conducted at a much lower cost to the patient.  
 
6.2 Environmental Impact  
Environmentally, there most likely will not be any major impacts on the natural 
environment. Our novel stainless mesh structure would allow the possibility for the single 
use scaffold to be sterilized and then recycled. Since there is no coating on the mesh there 
is no possibility for biological spreading to the ecosystem if recycled. There would be a 
reduction in biohazard decontamination due to the recyclability of our mesh however, our 
spent cell culture media would need to be properly disposed of. The system will have less 
of an environmental impact due to the generation of less potentially hazardous waste due 
to the efficiency of cell production compared to other, more complicated systems.  
Reduction in overall medication consumption due to MSC therapies would reduce 
the amount of medications improperly disposed into the environment. Exposure to such 
medications in the ecosystem can damage populations and subsequently impact the 
ecosystem.  
 
6.3 Societal Influence 
 The societal impact of production and marketing of our product would be a 
reduction in the stigma behind chronic diseases. Ordinary people would be impacted by 
our product because chronic disease impacts ordinary people. Fear of dealing with 
symptoms for the rest of one's life would be alleviated by the sales and marketing of our 
product by the treatment it provides. Alleviation of symptoms would reduce the use of 
powerful pain medication to deal with pain from chronic illness such as opioids, thus 
reducing the possibility of addiction from long term use.  
There would be the societal influence of hope now for people with chronic 
diseases. Ordinary people may also be more in favor of stem cell treatments because 
through our marketing and production more and more ordinary people with “ordinary” 
chronic diseases would be treated. Our product would help a large population of people 
46 
in turn persuade the people impacted by knowing someone with a chronic disease into 
accepting patient specific and novel treatments such as our product.  
 
6.4 Political Ramifications  
On the global market our product has the ability to lower some pharmaceutical 
sales of large companies that manufacture drugs for chronic illnesses. This may influence 
politically wise, big pharmaceutical companies monopolizing the manufacturing of 
certain drugs and price gauging them to ensure a high profit. The effect on other countries 
would be further research into chronic illness therapies via our MSC scaffold for patient 
specific therapies. Globally, the stigma around a chronic illness being life long and 
debilitating on quality of life would also be lowered with the MSC therapies being an 
option for treatment to alleviate and treat chronic illnesses.  
 
6.5 Ethical Concerns 
Ethically, our product has the patient’s quality of life at the forefront of the 
design. The MSC scaffold is designed to efficiently and quickly manufacture MSCs for 
patient specific treatments. Our product is designed to ensure no toxicity is in the cells 
when implanted in the patient and the cells will either be autologous or allogeneic cells to 
ensure ease of implantation in the body. Our product addresses not only alleviating 
symptoms of a chronic illness that cause pain and a lesser quality of life, but also has the 
promise of possibly curing chronic illness. 
 
6.6 Health and Safety Issues  
 Our project will influence the health of people by providing a viable and long 
term treatment for chronically ill patients. Successful implementation of our project into 
the pharmaceutical field would positively influence the health of people as patients with 
chronic diseases recover from their illness or symptoms are relieved. Relief of symptoms 
from our design would put people with chronic illnesses at less risk for injuries from 
symptoms that hinder mobility or sight.  
 For the people using our product to produce MSC’s in a lab setting our project 
will not require additional personal protective equipment than already necessary by the 
industry. Our project has no non byproducts that could be harmful to someone using or 
producing our scaffold. Our scaffold does not influence the personal safety of the user or 
the patients receiving therapies in a negative way. The project only poses the influence to 
positively affect health and safety. 
 
6.7 Manufacturability 
 The subject matter of our MQP project, the MSCs on the mesh scaffold, will 
initially be challenging to reproduce. Challenges are in obtaining patient specific or 
allogeneic MSCs for manufacturing for treatments. After initial manufacturing of the 
mesh scaffolds, seeding and harvesting techniques for the MSCs to get the highest yield 
will be fine-tuned resulting in high reproducibility of techniques for further production.   
The subject matter of our project can easily be reproduced by manufacturing 
stainless steel mesh and tailoring the sizes for any scale of bioreactor. Stainless steel 
mesh is already very reproducible therefore, the simple design of the layer meshed 
scaffold will be easy to reproduce on a large scale. Specifically, cutout molds of varying 
47 
sizes based on bioreactor volumes of the mesh discs can be created in order to increase 
manufacturing efficiency, repeatable quality of the product and to reduce manufacturing 
time. These circular mesh cutouts can then be stacked based on bioreactor volume on an 
assembly line. These techniques can be used when recreating the product in a scaled-up 
scenario.  
In order to reproduce our product, circular cutouts of the 304 stainless steel mesh 
will be cut out into equal sizes of equal diameters. The mesh cutouts should be placed in 
cell medium for 24 hours in order to allow the mesh to be fully soaked before finishing 
the scaffold. After 24 hours, 5 disks should be placed on top of one another and fanned 
out in a design where the pores do not fully overlap. After the 5 disks are arranged they 
should be secured in place. After sets of the soaked fan disks have been secured the 
fanned disks can be placed in a bioreactor for cell seeding and culturing. This product has 
the ability to be scaled for any size bioreactor by simply changing the diameter of the 
disks and following the rest of the protocol. 
 
6.8 Sustainability  
 Our project is sustainable because it does not have any known byproducts that 
could harm the environment. Stainless steel mesh is currently produced therefore there 
would not need to be the construction of any new factories or the harvesting of new raw 
materials that could influence the ecosystem. Less material needs to be used for a MSC 
therapy than currently used as well as an increased efficiency in production directly 
translates to a more energy efficient production. While our product is single use it has the 
ability to be recycled through proper sterilization since there is no biological coating on 
the mesh preventing it from being recycled with other stainless steel scraps.  
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Chapter 7: Discussion 
  
The project was designed in order to create a novel scalable scaffold for adherent stem 
cell culture within bioreactors in order to increase the ease and efficiency of stem cell production 
and harvesting in the pharmaceutical industry. The novel scaffold needed to be made of non-
corrosive, non-cytotoxic material that supported stem cell attachment and proliferation, while 
possessing advantages over the current gold-standard material. Such potential advantages 
included ease of production and manufacturing, having a reduced cost, requiring less treatment 
and preparation prior to use and enhancing ease of stem cell migration. The novel scaffold also 
needed a novel structure and architecture that would increase surface area to volume ratio within 
the bioreactor and surpass the current golden standard of 13,200 cm2/L, while also allowing for 
media flow, proper nutrient distribution and sufficient oxygen transport within the scaffold 
system. The scaffold also needed to ease the cell seeding process, increase seeding efficiency, 
surface utilization and harvesting efficiency (recovery rate of cells). Through the design of the 
scaffold and six tests, the scaffold was proven to meet several of the objectives listed above and 
be a superior alternative to the current gold-standard in stem cell culturing and production.  
 
7.1 Material Selection and Results 
The first step of the material selection process was guided by extensive literature review, 
specifically looking into materials that support cell attachment without inducing cell 
differentiation, are non-cytotoxic and can remain corrosion-free after being submerged within 
media suspension for an extended period of time. The literature review focused on materials that 
have been experimentally proven to fulfil the criteria listed above and to be suitable as substrates 
for adherent cell culture but have not been widely adopted within industry. Due to limitations 
posed by a limited access to sterilization methods, the material used in the scaffold design had to 
either be purchased pre-sterilized or withstand sterilization by autoclaving and isopropyl alcohol 
baths. This limitation in sterilization methods eliminated the choice of many polymers as 
substrate materials due to their low melting temperatures. The final material choices consisted of 
4 distinct materials including two polymers. The first polymer was polyurethane foam obtained 
in pre-sterilized condition. The use and testing of this material faced several major limitations. 
The first limitation was that the only means of cell retrieval was submerging the material in 
trypsin. The pore size and foam structure did not allow for proper trypsinization and resulted in -
19.81% daily growth rate. As a result of such a poor yield and the impossibility of cell retrieval 
this material couldn’t be used for the scaffold substrate. The second limitation was the 
opaqueness and porous nature of the material which impeded proper imaging under both a light 
and fluorescent microscope. The second polymer was liquid polystyrene made within the sterile 
conditions of the lab and coated onto glass slides. Three different types of polystyrene coatings 
were tested, solid polystyrene, porous polystyrene with a pore size of 50 nm and porous 
polystyrene with a pore size of 200 nm. Solid polystyrene had a 0% attachment and as a result 
yielded no cell count. The limitation of polystyrene was the inconsistent process of creating 
pores through the process of zinc oxide etching. Very often the zinc oxide particles that were 
used to create pores were not completely removed by 5% hydrochloric acid resulting in 
inconsistent surface topography across samples. However, this limitation and inconsistencies in 
the porous polystyrene samples are negligible, as the values of yielded cells and the doubling 
times on the porous polystyrene surfaces were often within an acceptable range of 
differentiation. The yielded cells and the doubling times on the porous polystyrene surfaces were 
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also significantly different, with the 50 nm porous polystyrene having an average yield of 
262,500 cells after 7 days and the 200 nm porous polystyrene having an average yield of 363,750 
cells after 7 days of culture. 
 
7.2 Structure Selection and Results 
The first step in the selection of potential structure and architectures for the novel 
scaffold was a literature review of structures in nature, various industries and everyday objects 
that possess a high surface area while not occupying a large volume. These structures were 
inspired by sea anemones, beehives and honeycombs, spider webs, shell and tube heat exchanger 
reactor, construction scaffolds, fiberglass insulation, hair-brushes and toilet paper rolls. 
Structures were first eliminated based on the moldability of the materials that could be used to 
create the selected architectures. As none of the materials that were available and accessible 
could be reasonably shaped in the form of flexible anemone tentacles or rigid and uniform 
honeycombs those structures were eliminated. Structures were then selected based on the 
greatest amount of surface area in the smallest volume that they could provide, which led to the 
selection of a cylinder design (much like a toilet paper roll) created out of mesh (much like a 
spider web) and a more simple design of stacked mesh cut outs. The stacked mesh cut outs 
yielded a surface area-to-volume ratio of 148,451 cm2/L which is more than 11 times greater 
than the ratio provided by microcarriers, the current gold standard. Another structure that was 
selected was the packed fiberglass design. The surface area-to-volume ratio for packed fiberglass 
was calculated to be 36,502 cm2/L, which is 2.8 times greater than the ratio provided by 
microcarriers. The measurement and calculation of surface area for the mesh and fiberglass came 
with accuracy limitations and assumptions of perfectly uniform wire diameters and constant 
rectangular size fiberglass pieces. These limitations and assumptions are acceptable and can be 
neglected for the sake of the design project as the average values of surface area for the mesh and 
fiberglass designs are significantly greater than those documented for microcarriers.  
 
7.3 Final Design Verification 
The final design verification process was cut short by the closure of the lab due to the 
COVID-19 pandemic. The preliminary closure of the lab resulted in the inability to continue any 
of the prior tests and conduct verification tests for the final scaffold design. The loss of two 
months of testing time resulted in a limited number of preformed tests and limited test results. 
None of the scheduled tests could be performed outside of the sanitary lab environment and 
without access to the incubators needed for cell culture. Thus, although the performed tests and 
calculations prove that the stainless steel mesh in cylindrical arrangement and in stacked disk 
arrangement provides more surface area per a unit of volume than the current golden standard of 
microcarriers and allows sufficient flow for the necessary nutrient distribution. Similarly, the 
fiberglass has proven to have more surface area per unit of volume than the current golden 
standard and still allow for sufficient media flow. Although not all of the verification testing was 
performed, the testing and the results that were obtained support the claim that our design 
possesses significant advantages over microcarriers and has the potential to significantly increase 
stem cell production in industry.  
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Chapter 8: Conclusions/ Recommendations 
 
 Current protocols and materials used for the mass production of Mesenchymal Stem Cells 
within a bioreactor is not as optimal as it can be. In the coming years with projected use of MSCs 
for research and medicine getting higher and higher, a new and improved scaffold within a 
bioreactor is needed. Current state of the art microcarriers are inefficient for seeding as well as 
harvesting at MSCs, leaving a need in the market for a new scaffold that could help reduce or 
remove these problems. In an attempt to improve upon these systems, this study looked at 
potential materials as well as scaffold designs that increase proliferation and numbers of MSCs. 
These were then combined and narrowed down to the three best candidates showing the most 
potential to be further studied: the Stainless Steel Mesh Packed Disks, the Stainless Steel Mesh 
Cylindrical Roll, and the Stainless Steel Mesh Cylindrical Roll. Through culturing cells on 
materials of similarly sized pieces, cell proliferation after several days could be both calculated, 
as well as visualized. Based on the results gathered it is believed that due to a higher surface area 
as well as capabilities for the cells to grow throughout the entire scaffold with more ease, this 
design has the potential to be more efficient at seeding and harvesting MSCs.  
 Multiple studies were planned to go more in depth and be able to better determine the 
most ideal scaffold structure, but due to COVID-19 causing labs to be closed down, these could 
not be completed. With this information it is believed that a design could have been backed up 
by data to truly show an efficiency at MSC proliferation that can-not be seen in microcarriers. 
Future recommendations would be to further study potential scaffold structures in order to 
determine a more ideal shape for seeding and harvesting. Although this study managed to look at 
fluid flow across the final three designs, being able to study the cell growth within a flowing 
system on these scaffolds would have supplied the most important numbers in showing their 
efficiency over microcarriers. This could also show the ease of harvest from these scaffolds 
providing more information on how it could be an overall improvement.  
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Appendix A: BrdU Photos 
 
Sample Existing Cells Proliferating Cells Existing & Proliferating Cells 
Control 
   
Plain Mesh 
   
Collagen 
Coated Mesh 
   
Soaked 
Mesh 
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Fiberglass 
   
200 nm Pore 
Polystyrene 
   
50 nm Pore 
Polystyrene 
   
  
53 
Appendix B: Preparation of Coated Plates 
Tissue culture plastic or glassware plates should be coated with 0.1% gelatin as follows: 
1. Add sufficient 0.1% gelatin solution to cover the entire surface of the cultureware plate. 
Use 10 mL volume for 10-cm plates and T75 flasks. Incubate for at least 30 minutes at 
room temperature. 
2. Just before use, aspirate the gelatin solution from the coated plate or flask. 
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Appendix C: Thawing of Mesenchymal Stem Cells 
1. Do not thaw the cells until the recommended medium and appropriately coated 0.1% 
gelatin plasticware and/or glassware are on hand. 
2. Remove the vial of Human Mesenchymal Stem Cells from liquid nitrogen and incubate 
in a 37°C water bath. Closely monitor until the cells are completely thawed. Maximum 
cell viability is dependent on the rapid and complete thawing of frozen cells. 
IMPORTANT: Do not vortex the cells. 
3. As soon as the cells are completely thawed, disinfect the outside of the vial with 70% 
ethanol. Proceed immediately to the next step. 
4. In a laminar flow hood, use a 1 or 2 mL pipette to transfer the cells to a sterile 15 mL 
conical tube. Be careful not to introduce any bubbles during the transfer process. 
5. Using a 10 mL pipette, slowly add dropwise 9 mL of Mesenchymal Stem Cell Expansion 
Medium or a suitable alternative of choice, pre-warmed to 37°C, to the 15 mL conical 
tube. 
IMPORTANT: Do not add the entire volume of media all at once to the cells. This may 
result in decreased cell viability due to osmotic shock. 
6. Gently mix the cell suspension by slowly pipetting up and down twice. Be careful to not 
introduce any bubbles. 
IMPORTANT: Do not vortex the cells. 
7. Centrifuge the tube at 300 x g for 2-3 minutes to pellet the cells. 
8. Decant as much of the supernatant as possible. Steps 5-8 are necessary to remove residual 
cryopreservative (DMSO). 
9. Resuspend the cells in a total volume of 10 mL of Mesenchymal Stem Cell Expansion 
Medium or a suitable alternative of choice, pre-warmed to 37°C, containing freshly added 
8 ng/mL FGF-2. 
10. Plate the cell suspension onto a 10-cm tissue culture plate or a T75 tissue culture flask. 
IMPORTANT: Seeding density should be 5,000-6,000 cells/cm2 
11. Maintain the cells at 37°C in a humidified incubator equilibrated with 5% CO2. 
12. The next day, exchange the medium with fresh Mesenchymal Stem Cell Expansion 
Medium (pre-warmed to 37°C) containing 8 ng/mL FGF-2*. Replace with fresh medium 
containing FGF-2 every two to three days thereafter. 
13. When the cells are approximately 80% confluent, they can be dissociated with Trypsin-
EDTA and passaged further or frozen for later use. 
NOTE: Depending on seeding density and passage number (i.e. later passages), cells may 
take longer to reach 80% confluency.  
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Appendix D: Expansion of Mesenchymal Stem Cells 
1. Subculture cells once they have reached approximately 80% confluence and are actively 
proliferating. 
IMPORTANT: Subculture cells before reaching 100% confluency. 
2. Carefully remove the medium from the 10-cm tissue culture plate containing the 
confluent layer of human mesenchymal stem cells. Apply 3-5 mL of Trypsin-EDTA 
Solution and incubate in a 37°C incubator for 3-5 minutes. 
3. Inspect the plate and ensure the complete detachment of cells by gently tapping the side 
of the plate with the palm of your hand. 
4. Add 5 mL Mesenchymal Stem Cell Expansion Medium to the plate. 
5. Gently rotate the plate to mix the cell suspension. Transfer the dissociated cells to a 15 
mL conical tube. 
6. Centrifuge the tube at 300 x g for 3-5 minutes to pellet the cells. 
7. Discard the supernatant 
8. Apply 2 mL Mesenchymal Stem Cell Expansion Medium (pre-warmed to 37°C) 
containing 8 ng/mL FGF-2 to the conical tube and resuspend the cells thoroughly. 
IMPORTANT: Do not vortex the cells. 
9. Count the number of cells using a hemocytometer. 
10. Plate the cells at a density of 5,000-6,000 cells per cm2 into the appropriate flasks, plates, 
or wells in Mesenchymal Stem Cell Expansion Medium containing 8 ng/mL FGF-2. 
11. Cells can be frozen in MSC growth media plus 10% DMSO at a density of 2X106 
cells/vial. 
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Appendix E: BrdU Assay Protocol 
1. Add 1.0 µl of BrdU stock solution per mL of culture medium to cells being assayed and 
incubate for 4 hours or the time required by the experimental protocol. 
2. Aspirate culture medium and wash cells in 2X in DPBS+. 
3. Aspirate DPBS+ and add ice cold (-20°C) methanol (1.0 mL/well for 24-well plate).  
Incubate for 10 minutes at -20°C. 
4. Aspirate methanol and wash with 1.0 mL PBS for 10 minutes (plates can be stored at 4°C 
with PBS in wells if analysis is not to be done right away. 
5. Aspirate PBS and add 1.5 N HCl (0.5 mL/well for 24-well or 0.25 ml/well for 48-well 
plate) and incubate at room temperature for 20 minutes.  
6.  Wash 3X with PBS, 5 minutes each. 
7.  If cells were cultured with serum, blocking is not necessary.  If cultured in a serum-free 
system, block at room temperature for at least 15 minutes with 5% FBS in PBS+0.05% 
Tween-20. 
8.  Dilute anti-BrdU antibody 1:100 in PBS +0.05% Tween-20. 
9. Add antibody solution at 150 µL/well for 24-well plate or 75 µL/well for 48-well plate) 
and incubate at room temperature for 30 minutes. 
10. Aspirate antibody solution and wash 3X with PBS for 5 minutes each. 
11. Add fluorescent dye conjugated secondary antibody diluted 1:500 in PBS+0.05% Tween-
20 (150 µL/well for 24-well plate or 75 µL/well for 48-well plate) and incubate at room 
temperature for 30 minutes. 
12. Wash 3X with PBS (without Tween). 
13. Add 0.5 µg/mL Hoechst 33342 to the last wash (stock is 1 mg/mL) and incubate for 10 
min at room temperature. 
14. Aspirate Hoechst solution, wash with PBS and add PBS (1.0 mL/well for 24-well or 0.5 
mL/well for 48-well plate). 
15. Cells are ready for observation by fluorescence microscopy.  Plates can be stored at 4°C 
wrapped in foil to protect from light. 
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Appendix F: Cell Media Composition 
 
For 50 ml of Cell Media: 
 
1. DMEM Basal Media - 44.0 mL 
2. Feligro (FBS) 10% - 5 mL 
3. Glulimax [100x] - 0.5 mL 
4. Pennstripe [100x] - 0.5 mL 
  
 
  
58 
Works Cited 
 
[1] Raghupathi, W., & Raghupathi, V. (2018). An empirical study of chronic diseases in the 
United States: a visual analytics approach to public health. International journal of 
environmental research and public health, 15(3), 431. 
[2] Who.int. (2019). WHO | 2. Background. [online] Available at: 
https://www.who.int/nutrition/topics/2_background/en/ [Accessed 16 Sep. 2019]. 
[3] National Institutes of Health (NIH). (2019). World’s older population grows dramatically. 
[online] Available at: https://www.nih.gov/news-events/news-releases/worlds-older-
population-grows-dramatically [Accessed 16 Sep. 2019]. 
[4] Weiss, M. L., Rao, M. S., Deans, R., & Czermak, P. (2016). Manufacturing cells for clinical 
use. Stem cells international. 2016. 
[5] Kim, N., & Cho, S. G. (2015). New strategies for overcoming limitations of mesenchymal 
stem cell-based immune modulation. International journal of stem cells, 8(1), 54. 
[6] Galipeau, J., & Sensébé, L. (2018). Mesenchymal stromal cells: clinical challenges and 
therapeutic opportunities. Cell Stem Cell, 22(6), 824-833. 
[7] Salzig, D., Leber, J., Merkewitz, K., Lange, M. C., Köster, N., & Czermak, P. (2016). 
Attachment, growth, and detachment of human mesenchymal stem cells in a chemically 
defined medium. Stem cells international, 2016. 
[8] António, M., Fernandes-Platzgummer, A., da Silva, C. L., & Cabral, J. M. (2016). Scalable 
microcarrier-based manufacturing of mesenchymal stem/stromal cells. Journal of 
biotechnology, 236, 88-109. 
[9] Trent, N. (2019, May 2). Mesenchymal Stem Cells 2019 Global Market Net Worth US$ 
2,518.5 Million Forecast By 2026 |. Retrieved from 
https://www.medgadget.com/2019/05/mesenchymal-stem-cells-2019-global-market-net-
worth-us-2518-5-million-forecast-by-2026.html 
[10] Godara, P., Mcfarland, C. D., & Nordon, R. E. (2008). Design of bioreactors for 
mesenchymal stem cell tissue engineering. Journal of Chemical Technology & 
Biotechnology, 83(4), 408–420. doi: 10.1002/jctb.1918 
[11] Hajat, C., & Stein, E. (2018). The global burden of multiple chronic conditions: A narrative 
review. Preventive medicine reports, 12, 284–293. 
https://doi.org/10.1016/j.pmedr.2018.10.008 
[12] Sav, A., King, M. A., Whitty, J. A., Kendall, E., McMillan, S. S., Kelly, F., Hunter, B., & 
Wheeler, A. J. (2015). Burden of treatment for chronic illness: a concept analysis and 
review of the literature. Health expectations : an international journal of public 
participation in health care and health policy, 18(3), 312–324. 
https://doi.org/10.1111/hex.12046 
[13] Bernell, S., & Howard, S. W. (2016). Use Your Words Carefully: What Is a Chronic 
Disease?. Frontiers in public health, 4, 159. https://doi.org/10.3389/fpubh.2016.00159 
[14] Pers, Y. M., Rackwitz, L., Ferreira, R., Pullig, O., Delfour, C., Barry, F., ... & Noël, D. 
(2016). Adipose mesenchymal stromal cell- based therapy for severe osteoarthritis of the 
knee: A phase i dose- escalation trial. Stem cells translational medicine, 5(7), 847-856. 
[15] Mancuso, P., Raman, S., Glynn, A., Barry, F., & Murphy, J. M. (2019). Mesenchymal 
stem cell therapy for osteoarthritis: the critical role of the cell secretome. Frontiers in 
bioengineering and biotechnology, 7. 
59 
[16] Kim, N., & Cho, S. G. (2013). Clinical applications of mesenchymal stem cells. The Korean 
journal of internal medicine, 28(4), 387–402. https://doi.org/10.3904/kjim.2013.28.4.387 
[17] Chen, A., Reuveny, S., & Oh, S. (2013). Application of human mesenchymal and 
pluripotent stem cell microcarrier cultures in cellular therapy: Achievements and future 
direction. Biotechnology Advances, 31(7), 1032–1046. 
https://doi.org/10.1016/j.biotechadv.2013.03.006 
[18] Ullah, I., Subbarao, R. B., & Rho, G. J. (2015). Human mesenchymal stem cells - current 
trends and future prospective. Bioscience reports, 35(2), e00191. 
https://doi.org/10.1042/BSR20150025 
[19] Merten O. W. (2015). Advances in cell culture: anchorage dependence. Philosophical 
transactions of the Royal Society of London. Series B, Biological sciences, 370(1661), 
20140040. https://doi.org/10.1098/rstb.2014.0040 
[20] Tsai, A. C. (2016). In Vitro Expansion and Functional Enhancement of Human 
Mesenchymal Stem Cell in Cell Therapy. 
[21] Athersys. (2019, January 23). Athersys Announces Positive Results From Its Exploratory 
Clinical Study of MultiStem® Cell Therapy for Treatment of Acute Respiratory Distress 
Syndrome (ARDS). Retrieved from https://www.athersys.com/investors/press-
releases/press-release-details/2019/Athersys-Announces-Positive-Results-From-Its-
Exploratory-Clinical-Study-of-MultiStem-Cell-Therapy-for-Treatment-of-Acute-
Respiratory-Distress-Syndrome-ARDS/default.aspx 
[22] Pall Corporation. (2019). Xpansion® Multiplate Bioreactor System. Retrieved from 
https://shop.pall.com/us/en/biotech/cell-culture/bioreactors/xpansion-multiplate-
bioreactor-system-zidhw7uq21i 
[23] Which Impeller Is Right for Your Cell Line? (2014, July 30). Retrieved from 
https://bioprocessintl.com/analytical/cell-line-development/which-impeller-is-right-for -
your-cell-line-183538/  
[24] Mizukami, A., & Swiech, K. (2018). Mesenchymal Stromal Cells: From Discovery to 
Manufacturing and Commercialization. Stem cells international, 2018, 4083921. 
doi:10.1155/2018/4083921 
[25] Mizukami, A., & Swiech, K. (2018). Mesenchymal Stromal Cells: From Discovery to 
Manufacturing and Commercialization. Stem cells international, 2018, 4083921. 
doi:10.1155/2018/4083921 
[26] Xcellerex XDR 10 single-use stirred-tank bioreactor. (n.d.). Retrieved from 
https://www.gelifesciences.com/en/us/shop/cell-culture-and-fermentation/stirred-tank-
bioreactors/stirred-tank-bioreactor-systems/xcellerex-xdr-10-single-use-stirred-tank-
bioreactor-p-05545. 
[27] Gupta, S. K., Dangi, A. K., Smita, M., Dwivedi, S., & Shukla, P. (2019). Effectual 
bioprocess development for protein production. In Applied Microbiology and 
bioengineering (pp. 203-227). Academic Press. 
[28] Cytodex. (n.d.). Cytodex 3 microcarriers (dry powder). Retrieved from 
https://www.cytivalifesciences.com/en/us/shop/cell-culture-and-
fermentation/microcarriers/cytodex-3-microcarriers-dry-powder-p-05925 
[29] Corning. (n.d.). Cell Culture Microcarriers: Cell Expansion and Yield. Retrieved from 
https://www.corning.com/worldwide/en/products/life-
sciences/products/bioprocess/microcarriers.html 
60 
[30] Tan, K., Shaul Reuveny, & Steve Kah Weng Oh. (2016). Recent advances in serum-free 
microcarrier expansion of mesenchymal stromal cells: Parameters to be optimized. 
Biochemical and Biophysical Research Communications, 473, 769–773. 
[31] Corning. (n.d.). Corning® Low Concentration Synthemax II Microcarriers, 500g Bottle. 
Retrieved from https://ecatalog.corning.com/life-sciences/b2c/US/en/Surfaces/Advanced-
Cell-Culture-Surfaces/Corning®-Microcarriers-for-Bioprocess-Scale-up/p/4623 
[32] Soure, A. M. D., Fernandes-Platzgummer, A., Silva, C. L. D., & Cabral, J. M. (2016). 
Scalable microcarrier-based manufacturing of mesenchymal stem/stromal cells. Journal 
of Biotechnology, 236, 88–109. doi: 10.1016/j.jbiotec.2016.08.007 
[33]  Li, B., Wang, X., Wang, Y., Gou, W., Yuan, X., Peng, J., ... & Lu, S. (2015). Past, present, 
and future of microcarrier-based tissue engineering. Journal of orthopaedic translation, 
3(2), 51-57 
[34] Couto, P. S. (2018, October). Growing MSC in Bioreactors: Part 2. Microcarriers. Retrieved 
from https://parentsguidecordblood.org/en/news/growing-msc-bioreactors-part-2-
microcarriers 
[35] Wu, C., Stoecklein, D., Kommajosula, A., Lin, J., Owsley, K., Ganapathysubramanian, B., 
& Di Carlo, D. (2018). Shaped 3D microcarriers for adherent cell culture and analysis. 
Microsystems & Nanoengineering, 4(1), 1–9. https://doi.org/10.1038/s41378-018-0020-7  
[36] PBS Biotech. (2014.). Vertical-Wheel. Retrieved from 
https://www.pbsbiotech.com/vertical-wheel.html. 
[37] Warnock J.N., Bratch K., Al-Rubeai M. (2005) Packed Bed Bioreactors. In: Chaudhuri J., 
Al-Rubeai M. (eds) Bioreactors for Tissue Sen, P., Nath, A., & Bhattacharjee, C. (2016). 
Packed-Bed Bioreactor and Its Application in Dairy, Food, and Beverage Industry. In 
Current Developments in Biotechnology and Bioengineering: Bioprocesses, Bioreactors 
and Controls (pp. 235–277). https://doi.org/10.1016/B978-0-444-63663-8.00009-4 
[38] Biocom Ag. (n.d.). Increase Your Culture Yields with Fibra-Cel® Disks. Retrieved from 
https://european-biotechnology.com/needful-things/products/product/increase-your-
culture-yields-with-fibra-celr-disks.html 
[39] Eppendorf. (n.d.). Fibra-Cel® Disks. Retrieved from https://online-shop.eppendorf.us/US-
en/Bioprocess-44559/Accessories-44562/Fibra-Cel-Disks-PF-67052.html 
[40] Butler M. (1987) Growth limitations in microcarrier cultures. In: Vertrebrate Cell Culture I. 
Advances in Biochemical Engineering/Biotechnology, vol 34. Springer, Berlin, 
Heidelberg 
[41] Chan, A. S. H., Coucouvanis, E., Tousey, S., Andersen, M. D., & Ni, J. H. T. (n.d.). 
Improved Expansion of MSC Without Loss of Differentiation Potential. Retrieved 
November 10, 2019, from https://www.rndsystems.com/resources/posters/improved-
expansion-msc-without-loss-differentiation-potential. 
[42] Cytodex. (2009, August). Cytodex™ surface microcarriers. Retrieved from 
https://www.cytivalifesciences.co.jp/catalog/pdf/18106061_cytodex.pdf  
[43] Nienow, A., Rafiq, Q., Coopman, K., & Hewitt, C. (2014). A potentially scalable method 
for the harvesting of hMSCs from microcarriers. 85(C), 79–88. 
https://doi.org/10.1016/j.bej.2014.02.005  
[44] Mesenchymal Stem Cell Culture Protocols. (2019). Retrieved from 
https://www.sigmaaldrich.com/technical-documents/protocols/biology/cell-
culture/mesenchymal-stem-cell-culture-protocols.html.  
[45] Yeatts, A. B., Choquette, D. T., & Fisher, J. P. (2013). Bioreactors to influence stem cell 
61 
fate:augmentation of mesenchymal stem cell signaling pathways via dynamic culture 
systems. Biochimica et Biophysica Acta (BBA)-General Subjects, 1830(2), 2470-2480.  
[46] Vina, E. R., & Kwoh, C. K. (2018). Epidemiology of osteoarthritis: literature update. 
Current opinion in rheumatology, 30(2), 160-167. 
[47] Volarevic, V., Markovic, B. S., Gazdic, M., Volarevic, A., Jovicic, N., Arsenijevic, N., … 
Stojkovic, M. (2018). Ethical and Safety Issues of Stem Cell-Based Therapy. 
International journal of medical sciences, 15(1), 36–45. doi:10.7150/ijms.21666 
[48] Vina, E. R., & Kwoh, C. K. (2018). Epidemiology of osteoarthritis: literature update.  
Current opinion in rheumatology, 30(2), 160-167. 
[49] Lawson, T., Kehoe, D. E., Schnitzler, A. C., Rapiejko, P. J., Der, K. A., Philbrick, K., ... &  
Murrell, J. R. (2017). Process development for expansion of human mesenchymal 
stromal cells in a 50 L single-use stirred tank bioreactor. Biochemical engineering 
journal, 120, 49-62. 
[50] Brindley, D., Moorthy, K., Lee, J. H., Mason, C., Kim, H. W., & Wall, I. (2011).  
Bioprocess forces and their impact on cell behavior: implications for bone regeneration 
therapy. Journal of tissue engineering, 2011. 
[51] Federal Remediation Technology Roundtable. (n.d.). Bioreator Hazard Analysis.  
Retrieved from https://frtr.gov/matrix2/health_safety/chapter_14.html. 
[52] Cona, Louis A. (2020). The Cost of Stem Cell Therapy in 2020. RSS, DVC Stem, Retrieved 
from www.dvcstem.com/post/stem-cell-therapy-cost-2020 
[53] Health and Economic Costs of Chronic Disease. (2020, March 23). Retrieved May 07, 2020, 
from https://www.cdc.gov/chronicdisease/about/costs/index.htm 
 
  
 
 
 
 
